<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96161</article-id><article-id pub-id-type="doi">10.7554/eLife.96161</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.96161.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Neurons enhance blood–brain barrier function via upregulating claudin-5 and VE-cadherin expression due to glial cell line-derived neurotrophic factor secretion</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Lu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0032-2045</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Zijin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mu</surname><given-names>Ruijing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Wenhan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhi</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Xiaodong</given-names></name><email>xdliu@cpu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Hanyu</given-names></name><email>shenyhy@cpu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Li</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8476-2007</contrib-id><email>liulee@cpu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01sfm2718</institution-id><institution>Department of Pharmacology, School of Pharmacy, China Pharmaceutical University</institution></institution-wrap><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Velasco</surname><given-names>Ivan</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tmp8f25</institution-id><institution>Universidad Nacional Autónoma de México</institution></institution-wrap><country>Mexico</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>30</day><month>10</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP96161</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-02-08"><day>08</day><month>02</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-02-09"><day>09</day><month>02</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.02.07.579396"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-05-29"><day>29</day><month>05</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96161.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-20"><day>20</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96161.2"/></event></pub-history><permissions><copyright-statement>© 2024, Yang et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Yang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-96161-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-96161-figures-v1.pdf"/><abstract><p>Blood–brain barrier (BBB) prevents neurotoxins from entering central nervous system. We aimed to establish and characterize an <italic>in vitro</italic> triple co-culture BBB model consisting of brain endothelial cells hCMEC/D3, astrocytoma U251 cells, and neuroblastoma SH-SY5Y cells. Co-culture of SH-SY5Y and U251 cells markedly enhanced claudin-5 and VE-cadherin expression in hCMEC/D3 cells, accompanied by increased transendothelial electrical resistance and decreased permeability. Conditioned medium (CM) from SH-SY5Y cells (S-CM), U251 cells (U-CM), and co-culture of SH-SY5Y and U251 cells (US-CM) also promoted claudin-5 and VE-cadherin expression. Glial cell line-derived neurotrophic factor (GDNF) levels in S-CM and US-CM were significantly higher than CMs from hCMEC/D3 and U-CM. Both GDNF and US-CM upregulated claudin-5 and VE-cadherin expression, which were attenuated by anti-GDNF antibody and GDNF signaling inhibitors. GDNF increased claudin-5 expression via the PI3K/AKT/FOXO1 and MAPK/ERK pathways. Meanwhile, GDNF promoted VE-cadherin expression by activating PI3K/AKT/ETS1 and MAPK/ERK/ETS1 signaling. The roles of GDNF in BBB integrity were validated using brain-specific <italic>Gdnf</italic> silencing mice. The developed triple co-culture BBB model was successfully applied to predict BBB permeability. In conclusion, neurons enhance BBB integrity by upregulating claudin-5 and VE-cadherin expression through GDNF secretion and established triple co-culture BBB model may be used to predict drugs’ BBB permeability.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>blood–brain barrier</kwd><kwd>IVIVC</kwd><kwd><italic>in vivo/in vitro</italic> correlation</kwd><kwd><italic>in vitro</italic> BBB model</kwd><kwd>brain endothelial cells</kwd><kwd>neurons</kwd><kwd>GDNF</kwd><kwd>glial cell line-derived neurotrophic factor</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82373943</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Xiaodong</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82173884</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82204511</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Hanyu</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012172</institution-id><institution>Double First Class University Plan</institution></institution-wrap></funding-source><award-id>CPU2022QZ21</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Li</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Jiangsu Funding Program for Excellent Postdoctoral Talent</institution></institution-wrap></funding-source><award-id>2022ZB305</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Hanyu</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2023M733897</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Hanyu</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Postgraduate Research &amp; Practice Innovation Program of Jiangsu Province</institution></institution-wrap></funding-source><award-id>KYCX24_1019</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Lu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The established triple co-culture blood-–brain barrier (BBB) model could be used for predicting drugs’ BBB permeability, and co-culture with neurons and astrocytes enhanced brain endothelial cells’ integrity by secreting GDNF, which upregulated claudin-5 and VE-cadherin expression.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>As a dynamic interface between the blood circulatory system and the central nervous system (CNS), the blood–brain barrier (BBB) maintains homeostasis and normal function of CNS by strictly regulating material exchange between the blood and brain (<xref ref-type="bibr" rid="bib60">Palmiotti et al., 2014</xref>). The maintenance of BBB is mainly attributed to the expression of tight junctions (TJ) and adherent junctions (AJ) between adjacent brain endothelial cells and a variety of drug transporters. However, as a double-edged sword that protects CNS function, BBB also restricts the transport of some drugs from blood to brain, leading to poor CNS therapeutic effects and even CNS treatment failure (<xref ref-type="bibr" rid="bib5">Banks, 2016</xref>).</p><p>Several <italic>in silico</italic>, <italic>in vitro</italic>, <italic>in situ</italic>, and <italic>in vivo</italic> methods have been developed to assess the permeability of drugs across BBB, but each method has its limitations (<xref ref-type="bibr" rid="bib28">Hanafy et al., 2021</xref>). The <italic>in situ</italic> brain perfusion (ISBP) is considered the ‘gold standard’ for assessing BBB permeability but there exist limits related to animal ethics. Moreover, ISBP is not suitable for human or high-throughput workflows. Thus, a suitable, accurate, and high-throughput <italic>in vitro</italic> BBB model is required to predict the permeability of drug candidates through BBB.</p><p>BBB is formed by neurovascular units (NVU), composed of neural (neurons, microglia, and astrocytes) and vascular components (vascular endothelial cells, pericytes, and vascular smooth muscle cells) (<xref ref-type="bibr" rid="bib62">Potjewyd et al., 2018</xref>). The constant crosstalk and interactions among these cells contribute to the structural and signaling-based regulation of transcellular and paracellular transport, control of BBB permeability, and regulation of cerebral circulation (<xref ref-type="bibr" rid="bib2">Arvanitis et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Muoio et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Potjewyd et al., 2018</xref>). Although brain microvascular endothelial cells (BMECs) are commonly utilized as an <italic>in vitro</italic> BBB model to assess drug permeability across BBB, <italic>in vitro</italic> mono-culture of BMECs tends to lose some unique characteristics without the support of other cell types. To overcome the drawbacks of mono-culture BBB models, a range of multicellular co-culture BBB models co-cultured with other NVU elements (such as astrocytes or pericytes) have been developed. Astrocytes are the most abundant glial cell type in brain (<xref ref-type="bibr" rid="bib14">Clasadonte and Prevot, 2018</xref>). Their terminal feet cover &gt;80% of the surface of capillaries to form interdigitating coverage without slits (<xref ref-type="bibr" rid="bib51">Mathiisen et al., 2010</xref>). In addition, astrocytes also contain several proteins related to the tight binding of the basement membrane. The <italic>in vitro</italic> multicellular co-culture BBB models composed of astrocytes, pericytes, and endothelial cells are considered to mimic the vascular structure and offer paracellular tightness in BBB (<xref ref-type="bibr" rid="bib35">Ito et al., 2019</xref>; <xref ref-type="bibr" rid="bib55">Nakagawa et al., 2009</xref>; <xref ref-type="bibr" rid="bib81">Watanabe et al., 2021</xref>).</p><p>Neurons also play a crucial role in the NVU and may be involved in the regulation of BBB function. The maturation of BBB in mice considerably overlaps with the establishment of neuronal activity (<xref ref-type="bibr" rid="bib11">Biswas et al., 2020</xref>). A study revealed that the conditioned medium (CM) collected from primary rat neurons also attenuated cell death caused by glucose–oxygen–serum deprivation (<xref ref-type="bibr" rid="bib45">Lin et al., 2016</xref>). Furthermore, the primary rat neurons were reported to affect the differentiation and formation of BMECs (<xref ref-type="bibr" rid="bib68">Savettieri et al., 2000</xref>; <xref ref-type="bibr" rid="bib69">Schiera et al., 2003</xref>; <xref ref-type="bibr" rid="bib85">Xue et al., 2013</xref>). Recent research reported that, compared with the double co-culture of hCMEC/D3 and 1321N1 (human astrocytoma cells), the triple co-culture of hCMEC/D3, 1321N1, and human neuroblastoma SH-SY5Y cells exhibited a higher transendothelial electrical resistance (TEER) (<xref ref-type="bibr" rid="bib6">Barberio et al., 2022</xref>). A similar report showed that co-cultivation of RBE4.B (rat brain capillary endothelial cells) and neurons resulted in the lower permeability of [<sup>3</sup>H] sucrose than RBE4.B cells grown alone (<xref ref-type="bibr" rid="bib70">Schiera et al., 2005</xref>). All these studies indicate that neurons, as the elements of the NVU, may be tightly connected to the formation and maintenance of BBB functions.</p><p>The aims of the study were: (1) to establish and characterize an <italic>in vitro</italic> triple co-culture BBB model consisting of human brain endothelial cells (hCMEC/D3), human astrocytoma cells (U251), and human neuroblastoma cells (SH-SY5Y); (2) to investigate whether neurons were involved in the formation and maintenance of BBB integrity and explore their underlying mechanisms. The integrity of BBB was evaluated by quantifying the leakage of both fluorescein and FITC-Dextran 3–5 kDa (FITC-Dex); (3) to validate the <italic>in vitro</italic> results through <italic>in vivo</italic> experiments. Finally, the <italic>in vivo</italic>/<italic>in vitro</italic> correlation assay was analyzed to prove that the triple co-culture BBB model could better predict the BBB penetration of CNS drugs compared with the mono-culture BBB model.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Establishment and characterization of the <italic>in vitro</italic> triple co-culture BBB model</title><p>Four types of BBB <italic>in vitro</italic> models were established to compare the contributions of U251 and SH-SY5Y cells to hCMEC/D3 cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). TEER values were measured during the co-culture (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). TEER values of the four <italic>in vitro</italic> BBB models gradually increased until day 6. On day 7, the TEER values showed a decreasing trend. Thus, 6-day co-culture period was used for subsequent experiments. The highest TEER values were observed in the triple co-culture BBB model, followed by double co-culture with U251 cells and double co-culture with SH-SY5Y cells BBB models, hCMEC/D3 cells mono-culture BBB model showed the lowest TEER values. We also measured the TEER values of U251 monolayer cells, and the results showed that U251 cells themselves also contributed to the physical barrier of the model (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The apparent permeability coefficient (<italic>P<sub>app</sub></italic>) values of fluorescein and FITC-Dex were measured to characterize the integrity of four BBB models (<xref ref-type="fig" rid="fig1">Figure 1D, E</xref>). Consistent with the TEER values, the triple co-culture BBB model showed the lowest permeability of fluorescein and FITC-Dex, followed by double co-culture with U251 cells and double co-culture with SH-SY5Y cells BBB models. It was noticed that monolayer of U251 cells itself also worked as a barrier, preventing the leakage of permeability markers, which may explain why the permeability of FITC-Dex in double co-culture model with U251 cells is lower than that in double co-culture model with SH-SY5Y cells (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Co-culture with SH-SY5Y, U251, and U251 + SH-SY5Y cells also enhanced the proliferation of hCMEC/D3 cells. Moreover, the promoting effect of SH-SY5Y cells was stronger than that of U251 cells (<xref ref-type="fig" rid="fig1">Figure 1G–I</xref>). Furthermore, hCMEC/D3 cells were incubated with basic fibroblast growth factor (bFGF), which promotes cell proliferation without affecting both claudin-5 and VE-cadherin expression (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). The results showed that incubation with bFGF increased cell proliferation and reduced permeabilities of fluorescein and FITC-Dex across hCMEC/D3 cell monolayer. However, the permeability reduction was less than that by double co-culture with U251 cells or triple co-culture. These results inferred that contribution of cell proliferation to the barrier function of hCMEC/D3 was minor (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The effects of co-culture with U251 and/or SH-SY5Y cells on the integrity of hCMEC/D3 and blood–brain barrier (BBB) function.</title><p>(<bold>A</bold>) Four different types of BBB models were prepared from hCMEC/D3 cells (h), SH-SY5Y cells (S), and U251 cells (U). (<bold>B</bold>) The transendothelial electrical resistance (TEER) of four models, and the TEER values in day 6 were compared. Blank: no cells. Four biological replicates per group. (<bold>C</bold>) The TEER of hCMEC/D3 and U251 cells monolayer. Four biological replicates per group. (<bold>D, E</bold>) The apparent permeability coefficient (<italic>P<sub>app</sub></italic>, ×10<sup>−6</sup> cm/s) of fluorescein (NaF) and FITC-Dextran 3–5 kDa (FITC-Dex) of four BBB models. Four biological replicates per group. (<bold>F</bold>) The <italic>P<sub>app</sub></italic> (×10<sup>−6</sup> cm/s) of NaF and FITC-Dex across the blank inserts, and hCMEC/D3 or U251 mono-culture models. Four biological replicates per group. The cell density (<bold>G</bold>), EdU incorporation (<bold>H</bold>) of hCMEC/D3 cells after mono/co-culturing. Three biological replicates per group. (<bold>I</bold>) Cell viability of hCMEC/D3 cells after mono/co-culturing. Four biological replicates per group. (<bold>J, K</bold>) The mRNA levels of tight junction proteins, adherent junction proteins, and transporters. Four biological replicates per group. The protein expression levels of claudin-5 (CLDN-5), ZO-1, occluding (<bold>L, M</bold>), VE-cadherin (VE-Cad), <italic>β</italic>-catenin, and BCRP (<bold>N, O</bold>) in hCMEC/D3 cells. Four biological replicates per group. The correlations between the <italic>P<sub>app</sub></italic> (×10<sup>−5</sup> cm/s) of NaF and claudin-5 expression (<bold>P</bold>), or VE-cadherin expression (<bold>Q</bold>). The correlation between <italic>P<sub>app</sub></italic> (×10<sup>−5</sup> cm/s) of FITC-Dex and claudin-5 expression (<bold>R</bold>), or VE-cadherin expression (<bold>S</bold>). The above data are shown as the mean ± SEM. For J and K, two technical replicates per biological replicate. One technical replicate per biological replicate for the rest. *p &lt; 0.05; **p &lt; 0.01 by one-way ANOVA test followed by Fisher’s LSD test, Welch’s ANOVA test, or Kruskal–Wallis test. The simple linear regression analysis was used to examine the presence of a linear relationship between two variables.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>The western blot raw images in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>The labeled western blot images in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Excel file containing summary data and data analysis of <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96161-fig1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The induced proliferation of hCMEC/D3 cells by basic fibroblast growth factor (bFGF) slightly reduced the permeability of cell layers.</title><p>EdU incorporation (<bold>A</bold>), cell viability (<bold>B</bold>), and apparent permeability coefficient (<italic>P<sub>app</sub></italic>, ×10<sup>−6</sup> cm/s) of fluorescein (<bold>C</bold>) or FITC-Dextran 3–5 kDa (<bold>D</bold>) of hCMEC/D3 cells treated with bFGF (6, 20, and 60 ng/ml) for 6 days. The above data are shown as the mean ± SEM. Four biological replicates per group. One technical replicate for each biological replicate. Statistical significance was determined using one-way ANOVA test followed by Fisher’s LSD test or Welch’s ANOVA test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig1-figsupp1-v1.tif"/></fig></fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Neurons and astrocytes upregulated claudin-5 and VE-cadherin expression in hCMEC/D3 cells due to glial cell line-derived neurotrophic factor (GDNF) secretion.</title><p>(<bold>A</bold>) Effects of conditioned medium (CM) on claudin-5 and VE-cadherin expression. Con: the normal medium; S-CM: the CM from SH-SY5Y cells; U-CM: the CM from U251 cells; US-CM: the CM from SH-SY5Y cells co-culture with U251 cells. (<bold>B</bold>) The mRNA expression levels of neurotrophic factors in hCMEC/D3, U251, and SH-SY5Y cells. (<bold>C</bold>) Concentrations of GDNF, basic fibroblast growth factor (bFGF), insulin-like growth factor-1 (IGF-1), and transforming growth factor-<italic>β</italic> (TGF-<italic>β</italic>) in the CMs. H-CM: the CM from hCMEC/D3 cells. Effects of GDNF (<bold>D</bold>), IGF-1 (<bold>E</bold>), bFGF (<bold>F</bold>), and TGF-<italic>β</italic> (<bold>G</bold>) on the expression of claudin-5 and VE-cadherin. The dosages have been marked in the figure. Effects of anti-GDNF antibody on the upregulation of claudin-5 and VE-cadherin expression induced by US-CM (<bold>H</bold>) or 200 pg/ml GDNF (<bold>I</bold>). (<bold>J</bold>) Effects of 200 pg/ml GDNF and US-CM on claudin-5 and VE-cadherin expression in primary rat brain microvascular endothelial cells. Effects of 3 μM RET tyrosine kinase inhibitor SSP-86 (SPP), and 5 μM Src family kinases inhibitor PP2 on the upregulation of claudin-5 and VE-cadherin induced by 200 pg/mL GDNF (<bold>K</bold>) and US-CM (<bold>L</bold>). Effects of SPP on the transendothelial electrical resistance (TEER) on day 6 (<bold>M</bold>), the permeability of NaF, and FITC-Dex (<bold>N</bold>) of the hCMEC/D3 mono-culture blood–brain barrier (BBB) model treating 200 pg/ml GDNF. Effects of PP2 on the TEER on day 6 (<bold>O</bold>), the permeability of NaF, and FITC-Dex (<bold>P</bold>) of the hCMEC/D3 mono-culture BBB model treating 200 pg/ml GDNF. Effects of SPP on the TEER on day 6 (<bold>Q</bold>), the permeability of NaF, and FITC-Dex (<bold>R</bold>) of the triple co-culture BBB model. Effects of PP2 on the TEER on day 6 (<bold>S</bold>), the permeability of NaF, and FITC-Dex (<bold>T</bold>) of the triple co-culture BBB model. The above data are shown as the mean ± SEM. Four biological replicates per group. For B and C, two technical replicates per biological replicate. One technical replicate per biological replicate for the rest. *p &lt; 0.05; **p &lt; 0.01 by one-way ANOVA test followed by Fisher’s LSD test, Welch’s ANOVA test, or Kruskal–Wallis test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>The western blot raw images in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>The labeled western blot images in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Excel file containing summary data and data analysis of <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96161-fig2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig2-v1.tif"/></fig><p>The paracellular barrier of BBB is also associated with TJs, AJs, and transporters (<xref ref-type="bibr" rid="bib1">Abbott, 2013</xref>). The mRNA levels of TJs (claudin-5, ZO-1, and occludin), AJs (VE-cadherin and <italic>β</italic>-catenin), and transporters (P-gp, BCRP, OCT-1, OCT-2, OAT-3, and OATP1A1) in hCMEC/D3 cells from the four BBB models were analyzed using quantitative real-time PCR (qPCR) (<xref ref-type="fig" rid="fig1">Figure 1J, K</xref>). Compared with hCMEC/D3 cell mono-culture model, double co-culture with SH-SY5Y, double co-culture with U251, and triple co-culture BBB models showed markedly increases in claudin-5, VE-cadherin, <italic>β</italic>-catenin, and BCRP mRNA expression. Expression of corresponding proteins was measured using western blot (<xref ref-type="fig" rid="fig1">Figure 1L–O</xref>). Notably increased claudin-5 expression was detected in double co-culture with SH-SY5Y cells and triple co-culture BBB models, while VE-cadherin expression was markedly increased in double co-culture with U251 cells and triple co-culture BBB models. Expression levels of other TJ proteins (ZO-1 and occludin) and AJ protein (<italic>β</italic>-catenin) were unaltered. The expression of BCRP was slightly affected by co-cultivation with U251 cells. Significant negative correlations were found between <italic>P<sub>app</sub></italic> values of fluorescein and the expression of claudin-5 or VE-cadherin. <italic>P<sub>app</sub></italic> values of FITC-Dex were also negatively correlated to the expression levels of claudin-5 or VE-cadherin (<xref ref-type="fig" rid="fig1">Figure 1P–S</xref>). These results indicate that the decreased permeability of fluorescein and FITC-Dex mainly results from the upregulated expression of both claudin-5 and VE-cadherin.</p></sec><sec id="s2-2"><title>Neurons and astrocytes upregulated the expression of claudin-5 and VE-cadherin by glial cell line-derived neurotrophic factor secretion</title><p>The hCMEC/D3 cells did not direct contact with U251 or SH-SY5Y cells in the double co-culture and triple co-culture BBB models, indicating that cell–cell interaction between U251, SH-SY5Y, and hCMEC/D3 cells relied on secreted active factors. To test this hypothesis, the effects of CM from SH-SY5Y cells (S-CM), U251 cells (U-CM), and co-culture of SH-SY5Y and U251 cells (US-CM) on the expression of claudin-5 and VE-cadherin in hCMEC/D3 cells were analyzed (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Both S-CM, U-CM, and US-CM markedly increased the expression of claudin-5 and VE-cadherin. US-CM showed the strongest induction effects on claudin-5 and VE-cadherin.</p><p>To investigate which cytokines were involved in the promotion of hCMEC/D3 cell integrity by U251 and SH-SY5Y cells, the mRNA expression levels of various cytokines in these three types of cells were compared. The results showed that U251 or SH-SY5Y cells exhibited significantly higher expression levels of glial cell line-derived neurotrophic factor (GDNF), nerve growth factor, insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor, bFGF, and transforming growth factor-<italic>β</italic> (TGF-<italic>β</italic>) compared to hCMEC/D3 cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Furthermore, the mRNA expression of GDNF, IGF-1, TGF-<italic>β</italic>, and bFGF in SH-SY5Y cells was higher than those in U251 cells.</p><p>In these cytokines, GDNF (<xref ref-type="bibr" rid="bib21">Dong and Ubogu, 2018</xref>; <xref ref-type="bibr" rid="bib34">Igarashi et al., 1999</xref>; <xref ref-type="bibr" rid="bib72">Shimizu et al., 2012</xref>), bFGF (<xref ref-type="bibr" rid="bib71">Shimizu et al., 2011</xref>; <xref ref-type="bibr" rid="bib79">Wang et al., 2016</xref>), IGF-1 (<xref ref-type="bibr" rid="bib37">Ko et al., 2009</xref>; <xref ref-type="bibr" rid="bib57">Nowrangi et al., 2019</xref>), and TGF-<italic>β</italic> (<xref ref-type="bibr" rid="bib27">Fu et al., 2021</xref>) have been reported to promote BBB integrity. Thus, the concentrations of GDNF, bFGF, IGF-1, and TGF-<italic>β</italic> in the CMs were measured (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The results showed that levels of GDNF, bFGF, and IGF-1 in S-CM and US-CM were significantly higher than CMs from hCMEC/D3 cells (H-CM) and U-CM, but levels of TGF-<italic>β</italic> in S-CM and U-CM were lower than those in H-CM. Interestingly, the level of IGF-1 in US-CM was remarkably lower than that in S-CM, indicating that U251 cells suppressed IGF-1 secretion from SH-SY5Y. The effects of GDNF, bFGF, IGF-1, and TGF-<italic>β</italic> on the expression of claudin-5 and VE-cadherin were investigated (<xref ref-type="fig" rid="fig2">Figure 2D–G</xref>). Among the four tested neurotrophic factors, only GDNF induced the expression of claudin-5 and VE-cadherin in a concentration-dependent manner (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). In contrast, a high level (5 ng/ml) of TGF-<italic>β</italic> slightly downregulated claudin-5 expression (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). These results demonstrate that upregulation of claudin-5 and VE-cadherin expression by US-CM are attributed to secreted GDNF.</p><p>To provide additional verification of the deduction, anti-GDNF antibody was used to neutralize exogenous and endogenous GDNF in culture medium. Consistent with our expectation, the anti-GDNF antibody concentration-dependent reversed the US-CM-induced claudin-5 and VE-cadherin expression (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Furthermore, GDNF-induced upregulation of claudin-5 and VE-cadherin expression was also reversed by the anti-GDNF antibody (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). The induction effects of US-CM and GDNF on the claudin-5 and VE-cadherin expression in hCMEC/D3 cells were also confirmed in primary rat BMECs (<xref ref-type="fig" rid="fig2">Figure 2J</xref>).</p><p>GDNF forms a heterohexameric complex with two GFR<italic>α</italic>1 molecules and two RET receptors to activate the GDNF–GFR<italic>α</italic>1–RET signaling (<xref ref-type="bibr" rid="bib25">Fielder et al., 2018</xref>). The RET receptor tyrosine kinase inhibitor SPP-86 (<xref ref-type="bibr" rid="bib8">Bhallamudi et al., 2021</xref>) and Src-type kinase inhibitor PP2 (<xref ref-type="bibr" rid="bib53">Morita et al., 2006</xref>) were used to further investigate whether GDNF upregulated the expression of claudin-5 and VE-cadherin in hCMEC/D3 cells by activating the GDNF–GFR<italic>α</italic>1–RET signaling pathway. Both SPP-86 and PP2 markedly attenuated claudin-5 and VE-cadherin expression induced by GDNF (<xref ref-type="fig" rid="fig2">Figure 2K</xref>) and US-CM (<xref ref-type="fig" rid="fig2">Figure 2L</xref>).</p><p>The contributions of GDNF-induced claudin-5 and VE-cadherin expression to TEER and permeability were investigated using hCMEC/D3 cells mono-culture BBB model. GDNF significantly increased TEER values (<xref ref-type="fig" rid="fig2">Figure 2M, O</xref>) and decreased the permeability of fluorescein and FITC-Dex (<xref ref-type="fig" rid="fig2">Figure 2N, P</xref>), which were almost abolished by SPP-86 or PP2. Furthermore, treatment with SPP-86 or PP2 completely reversed the increased TEER values (<xref ref-type="fig" rid="fig2">Figure 2Q, S</xref>) and decreased permeability of fluorescein and FITC-Dex (<xref ref-type="fig" rid="fig2">Figure 2R, T</xref>) in the triple co-culture BBB model. These results indicate that neurons but also astrocytes upregulate claudin-5 and VE-cadherin expression in hCMEC/D3 cells by secreting GDNF. Subsequently, GDNF induces claudin-5 and VE-cadherin expression by activating GDNF–GFR<italic>α</italic>1–RET signaling.</p></sec><sec id="s2-3"><title>GDNF-induced claudin-5 and VE-cadherin expression of hCMEC/D3 by activating the PI3K/AKT and MAPK/ERK pathways</title><p>GDNF exerts its biological activities by activating several signaling pathways, including the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT), mitogen-activated protein kinase (MAPK)/extracellular regulated kinase (ERK), MAPK/c-Jun N-terminal kinase (JNK), and MAPK/ p38 pathways (<xref ref-type="bibr" rid="bib25">Fielder et al., 2018</xref>). The effects of the PI3K/AKT, MAPK/ERK, MAPK/JNK, and MAPK/p38 pathway inhibitors LY294002 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), U0126 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), SP600125 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), and SB203580 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), respectively, on GDNF-induced claudin-5 and VE-cadherin expression in hCMEC/D3 cells were investigated. GDNF increased claudin-5 and VE-cadherin expression, accompanied by the phosphorylation of AKT (p-AKT) and ERK (p-ERK). However, it did not stimulate the phosphorylation of JNK and p38. SPP-86, LY29002, and U0126 significantly suppressed GDNF-induced claudin-5 and VE-cadherin expression, while SP600125 and SB203580 had almost no effect on GDNF-induced claudin-5 and VE-cadherin expression. GDNF-induced phosphorylation of AKT and ERK was also markedly attenuated by the anti-GDNF antibody (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Similarly, US-CM remarkably upregulated the expression of claudin-5, VE-cadherin, p-AKT, and p-ERK, which were also markedly reversed by SPP-86, LY29002, U0126, or anti-GDNF antibody (<xref ref-type="fig" rid="fig3">Figure 3F–J</xref>). These findings indicate that GDNF induces the expression of claudin-5 and VE-cadherin in hCMEC/D3 cells by activating both the PI3K/AKT and MAPK/ERK pathways.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Glial cell line-derived neurotrophic factor (GDNF)-induced claudin-5 and VE-cadherin expression in hCMEC/D3 cells by activating the PI3K/AKT and MAPK/ERK signaling.</title><p>(<bold>A</bold>) Effects of 3 μM LY294002 (LY) on the levels of claudin-5, VE-cadherin, and p-AKT/AKT in hCMEC/D3 cells stimulated by 200 pg/ml GDNF. (<bold>B</bold>) Effects of 2 μM U0126 (U0) on the levels of claudin-5, VE-cadherin, and p-ERK/ERK in hCMEC/D3 cells stimulated by 200 pg/ml GDNF. (<bold>C</bold>) Effects of 5 μM SP600125 (SP) on the levels of claudin-5, VE-cadherin, and p-JNK/JNK in hCMEC/D3 cells stimulated by 200 pg/ml GDNF. (<bold>D</bold>) Effects of 2 μM SB203580 (SB) on the levels of claudin-5, VE-cadherin, and p-p38/p38 in hCMEC/D3 cells stimulated by 200 pg/ml GDNF. (<bold>E</bold>) Effects of anti-GDNF antibody on the GDNF-induced p-AKT/AKT and p-ERK/ERK ratios. (<bold>F</bold>) Effects of 3 μM LY on the levels of claudin-5, VE-cadherin, and p-AKT/AKT in hCMEC/D3 cells stimulated by US-CM. (<bold>G</bold>) Effects of 2 μM U0 on the levels of claudin-5, VE-cadherin, and p-ERK/ERK in hCMEC/D3 cells stimulated by US-CM. (<bold>H</bold>) Effects of 5 μM SP on the levels of claudin-5, VE-cadherin, and p-JNK/JNK in hCMEC/D3 cells stimulated by US-CM. (<bold>I</bold>) Effects of 2 μM SB on the levels of claudin-5, VE-cadherin, and p-p38/p38 in hCMEC/D3 cells stimulated by US-CM. (<bold>J</bold>) Effects of anti-GDNF antibody on the US-CM-induced p-AKT/AKT and p-ERK/ERK ratios. The above data are shown as the mean ± SEM. Four biological replicates per group. One technical replicate for each biological replicate. *p &lt; 0.05; **p &lt; 0.01 by one-way ANOVA test followed by Fisher’s LSD test or Welch’s ANOVA test.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>The western blot raw images in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>The labeled western blot images in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Excel file containing summary data and data analysis of <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96161-fig3-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig3-v1.tif"/></fig></sec><sec id="s2-4"><title>GDNF upregulated the claudin-5 expression in hCMEC/D3 cells by activating the PI3K/AKT/FOXO1 pathway</title><p>Claudin-5 is negatively regulated by the transcriptional repressor forkhead box O1 (FOXO1) (<xref ref-type="bibr" rid="bib7">Beard et al., 2020</xref>). FOXO1 is also an important target of PI3K/AKT signaling. FOXO1 phosphorylation results in FOXO1 accumulation in the cytoplasm (<xref ref-type="bibr" rid="bib87">Zhang et al., 2011</xref>) and lowers its level in the nucleus. Here, we investigated whether GDNF-induced claudin-5 expression is involved in FOXO1 nuclear exclusion. As shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, both GDNF and US-CM significantly enhanced FOXO1 phosphorylation (p-FOXO1). Similarly, GDNF and US-CM increased the levels of phosphorylated and unphosphorylated FOXO1 in the cytoplasm and decreased the levels of nuclear FOXO1 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Whether FOXO1 was involved in the GDNF-induced regulation of claudin-5 and VE-cadherin expression was investigated in hCMEC/D3 cells transfected with <italic>FOXO1</italic> small interfering RNA (siRNA). Silencing <italic>FOXO1</italic> significantly decreased FOXO1 levels in both whole-cell lysates and nucleus of hCMEC/D3 cells (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), demonstrating <italic>FOXO1</italic> silencing efficacy. Consistent with our expectation, silencing <italic>FOXO1</italic> upregulated the expression of claudin-5 rather than VE-cadherin expression (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). In contrast, high levels of FOXO1 were observed in both whole-cell lysates and nucleus of hCMEC/D3 cells that were transfected with plasmids containing <italic>FOXO1</italic>. Meanwhile, <italic>FOXO1</italic> overexpression resulted in a decrease in both basal and GDNF-induced claudin-5 expression (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), consistent with the known role of FOXO1 on claudin-5 expression.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Glial cell line-derived neurotrophic factor (GDNF) induced the claudin-5 expression in hCMEC/D3 cells by activating the PI3K/AKT/FOXO1 pathway.</title><p>Effects of US-CM and GDNF on the phosphorylated FOXO1 (p-FOXO1)/FOXO1 ratio, total FOXO1 expression (<bold>A</bold>), cytoplasmic p-FOXO1, cytoplasmic FOXO1, and nuclear FOXO1 expression (<bold>B</bold>). The expression levels of total and nuclear FOXO1 (<bold>C</bold>), claudin-5, and VE-cadherin (<bold>D</bold>) in hCMEC/D3 cells transfected with <italic>FOXO1</italic> siRNA (siFOXO1). NC: negative control. (<bold>E</bold>) Effects of <italic>FOXO1</italic> overexpression (FOXO1-OE) and GDNF on the expression levels of claudin-5, total FOXO1, and nuclear FOXO1. FOXO1-NC: negative control plasmids. (<bold>F</bold>) Effects of LY and U0 on GDNF-induced alterations of total p-FOXO1/FOXO1 ratio, cytoplasmic p-FOXO1, cytoplasmic FOXO1, and nuclear FOXO1 expression. (<bold>G</bold>) Effects of LY on the claudin-5 expression upregulated by siFOXO1. The above data are shown as the mean± SEM. Four biological replicates per group. One technical replicate for each biological replicate. *p &lt; 0.05; **p &lt; 0.01 by one-way ANOVA test followed by Fisher’s LSD test, Welch’s ANOVA test, or Kruskal–Wallis test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>The western blot raw images in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>The labeled western blot images in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Excel file containing summary data and data analysis of <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96161-fig4-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The contribution of VE-cadherin on the glial cell line-derived neurotrophic factor (GDNF)-induced claudin-5 expression.</title><p>Effects of the VE-cadherin siRNA (siVE-Cad) on mRNA expression of VE-cadherin (<bold>A</bold>) and claudin-5 (<bold>B</bold>). Effects of siVE-Cad and GDNF on claudin-5 and VE-cadherin protein expression (<bold>C</bold>). NC: negative control plasmids. The above data are shown as the mean ± SEM. Four biological replicates per group. Two technical replicates for A and B and one technical replicate for C. Statistical significance was determined using unpaired <italic>t</italic>-test or one-way ANOVA test followed by Fisher’s LSD test.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>The western blot raw images in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>The labeled western blot images in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>Excel file containing summary data and data analysis of <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96161-fig4-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Several reports have demonstrated that nuclear localization of FOXO1 is modulated by multiple pathways, including the PI3K/AKT (<xref ref-type="bibr" rid="bib76">Tang et al., 1999</xref>) and MAPK/ERK (<xref ref-type="bibr" rid="bib3">Asada et al., 2007</xref>) pathways. The effects of LY294002 and U0126 on GDNF-induced FOXO1 phosphorylation were measured in hCMEC/D3 cells. LY294002, but not U0126, significantly reversed the GDNF-induced alterations in total p-FOXO1, cytoplasmic p-FOXO1, cytoplasmic FOXO1, and nuclear FOXO1 (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Furthermore, LY294002 reversed the upregulation of claudin-5 expression induced by <italic>FOXO1</italic> siRNA and GDNF (<xref ref-type="fig" rid="fig4">Figure 4G</xref>).</p><p>It was reported that VE-cadherin also upregulates claudin-5 via inhibiting FOXO1 activities (<xref ref-type="bibr" rid="bib75">Taddei et al., 2008</xref>). Effect of VE-cadherin on claudin-5 was studied in hCMEC/D3 cells silencing VE-cadherin. It was not consistent with Taddei et al. that silencing VE-cadherin only slightly decreased the mRNA level of claudin-5 without significant difference. Furthermore, basal and GDNF-induced claudin-5 protein levels were unaltered by silencing VE-cadherin (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Thus, the roles of VE-cadherin in regulation of claudin-5 in BBB should be further investigated.</p></sec><sec id="s2-5"><title>GDNF upregulated VE-cadherin expression in hCMEC/D3 cells by activating the PI3K/AKT/ETS1 and MAPK/ERK/ETS1 signaling pathways</title><p>E26 oncogene homolog 1 (ETS1) is a transcription factor that binds to the ETS-binding site located in the proximal region of the VE-cadherin promoter, hence regulating the expression of VE-cadherin (<xref ref-type="bibr" rid="bib39">Lelièvre et al., 2000</xref>; <xref ref-type="bibr" rid="bib50">Luo et al., 2022</xref>). Activation of the PI3K/AKT (<xref ref-type="bibr" rid="bib31">He et al., 2023</xref>; <xref ref-type="bibr" rid="bib33">Hui et al., 2018</xref>) and MAPK/ERK (<xref ref-type="bibr" rid="bib80">Watanabe et al., 2004</xref>) pathways was reported to upregulate the expression of ETS1. The previous results showed that GDNF-induced VE-cadherin and claudin-5 expression in hCMEC/D3 cells by activating the PI3K/AKT and MAPK/ERK pathways. Therefore, we hypothesized that GDNF modulated ETS1 levels to promote VE-cadherin and claudin-5 expression through PI3K/AKT and MAPK/ERK signaling pathways. Both US-CM and GDNF significantly increased total (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) and nuclear ETS1 expression (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). LY294002 and U0126 markedly attenuated GDNF-induced total (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) and nuclear ETS1 expression (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). To further confirm the involvement of the PI3K/AKT/ETS1 and MAPK/ERK/ETS1 pathways in GDNF-induced VE-cadherin expression, ETS1 in hCMEC/D3 cells was knocked down using <italic>ETS1</italic> siRNA. <italic>ETS1</italic> silencing saliently declined the expression levels of total (<xref ref-type="fig" rid="fig5">Figure 5E</xref>) and nuclear (<xref ref-type="fig" rid="fig5">Figure 5F</xref>) ETS1 in hCMEC/D3 cells, demonstrating silencing efficacy. In <italic>ETS1</italic> silencing hCMEC/D3 cells, GDNF no longer induced the expression of total (<xref ref-type="fig" rid="fig5">Figure 5E</xref>) and nuclear (<xref ref-type="fig" rid="fig5">Figure 5F</xref>) ETS1. Moreover, <italic>ETS1</italic> silencing substantially downregulated VE-cadherin expression and attenuated GDNF-induced VE-cadherin expression, while having minimal impact on both basal and GDNF-induced claudin-5 expression (<xref ref-type="fig" rid="fig5">Figure 5G</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Glial cell line-derived neurotrophic factor (GDNF)-induced VE-cadherin expression in hCMEC/D3 cells by activating the PI3K/AKT/ETS1 and MAPK/ERK/ETS1 pathways.</title><p>Effects of US-CM and GDNF on total (<bold>A</bold>) and nuclear (<bold>B</bold>) ETS1 expression. Effects of LY and U0 on 200 pg/ml GDNF-induced total (<bold>C</bold>) and nuclear (<bold>D</bold>) ETS1 expression. Expression levels of total (<bold>E</bold>) and the nuclear ETS1 (<bold>F</bold>) in hCMEC/D3 cells after knocking down <italic>ETS1</italic> with siRNA (siETS1). (<bold>G</bold>) Effects of GDNF and siETS1 on the expression of VE-cadherin and claudin-5. The above data are shown as the mean ± SEM. Four biological replicates per group. One technical replicate for each biological replicate. *p &lt; 0.05; **p &lt; 0.01 by one-way ANOVA test followed by Fisher’s LSD test.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>The western blot raw images in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>The labeled western blot images in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Excel file containing summary data and data analysis of <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96161-fig5-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig5-v1.tif"/></fig></sec><sec id="s2-6"><title>Brain GDNF deficiency increased BBB permeability partly due to the impairment of claudin-5 and VE-cadherin expression</title><p>To further demonstrate the positive effects of GDNF on BBB maintenance, GDNF in mice brains was knocked down via intracerebroventricular (<italic>i.c.v</italic>) injection of AAV-PHP.eB packaged with <italic>Gdnf</italic> short hairpin RNA (shRNA) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Knockdown efficiency was confirmed through western blotting (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Consistent with <italic>in vitro</italic> results, GDNF knockdown greatly downregulated claudin-5 and VE-cadherin expression in the mice brains (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The integrity of BBB was assessed by examining the brain distributions of fluorescein and FITC-Dex. The results showed that specifically knocking down brain GDNF little affected plasma levels of fluorescein (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and FITC-Dex (<xref ref-type="fig" rid="fig6">Figure 6F</xref>), but significantly elevated the concentrations of fluorescein (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) and FITC-Dex (<xref ref-type="fig" rid="fig6">Figure 6G</xref>) in the brains, leading to notable increases in the brain-to-plasma concentration ratios of two probes (<xref ref-type="fig" rid="fig6">Figure 6E, H</xref>). These alterations were consistent with the decline in claudin-5 and VE-cadherin expression. In addition, significant reductions in the levels of p-AKT (<xref ref-type="fig" rid="fig6">Figure 6I</xref>), p-ERK (<xref ref-type="fig" rid="fig6">Figure 6J</xref>), p-FOXO1 (<xref ref-type="fig" rid="fig6">Figure 6K</xref>), and ETS1 expression (<xref ref-type="fig" rid="fig6">Figure 6L</xref>) were observed in the brains of <italic>Gdnf</italic> knockdown mice.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The deficiency of brain glial cell line-derived neurotrophic factor (GDNF) in mice increased the permeability of blood–brain barrier (BBB) and reduced claudin-5 and VE-cadherin expression in mice brains.</title><p>(<bold>A</bold>) Experimental configuration of AAV-GFP (shNC) or AAV-sh<italic>Gdnf</italic> (sh<italic>Gdnf</italic>) intracerebroventricular injection. (<bold>B</bold>) Effects of brain-specific <italic>Gdnf</italic> silencing on the expression levels of GDNF, claudin-5, and VE-cadherin in the brains. Effects of brain-specific <italic>Gdnf</italic> silencing on NaF levels in plasma (<bold>C</bold>), brain (<bold>D</bold>), and the ratio of brain to plasma (<bold>E</bold>). Effects of brain-specific <italic>Gdnf</italic> silencing on FITC-Dex levels in plasma (<bold>F</bold>), brain (<bold>G</bold>), and the ratio of brain to plasma (<bold>H</bold>). The expression ratios of p-AKT/AKT (<bold>I</bold>), p-ERK/ERK (<bold>J</bold>), and p-FOXO1/FOXO1 (<bold>K</bold>) in the brains of <italic>Gdnf</italic> silencing mice. (<bold>L</bold>) The expression level of ETS1 in the brains of <italic>Gdnf</italic> silencing mice. The above data are shown as the mean ± SEM. Six biological replicates per group. One technical replicate for each biological replicate. *p &lt; 0.05; **p &lt; 0.01 by unpaired <italic>t</italic>-test, unpaired <italic>t</italic>-test with Welch’s correction, or Mann–Whitney test.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>The western blot raw images in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>The labeled western blot images in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96161-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Excel file containing summary data and data analysis of <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96161-fig6-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig6-v1.tif"/></fig></sec><sec id="s2-7"><title>The triple co-culture BBB model better predicted the permeabilities of drugs across BBB</title><p>In this study, 18 drugs were utilized to further investigate the superiority of the triple co-culture BBB model over the hCMEC/D3 mono-culture BBB model. The <italic>P<sub>app</sub></italic> of 18 drugs from the apical to the basolateral side based on the hCMEC/D3 mono-culture (<italic>P<sub>app, Mono</sub></italic>) and triple co-culture (<italic>P<sub>app, Triple</sub></italic>) BBB models are measured and listed in <xref ref-type="table" rid="table1">Table 1</xref>. The results showed that <italic>P<sub>app, Triple</sub></italic> values of all tested drugs were lower than the <italic>P<sub>app, Mono</sub></italic> values. Significant differences were observed in 14 out of 18 drugs. The predicted permeability coefficient-surface area product values (<italic>PS</italic>) of the tested drugs were, respectively, calculated based on their <italic>P<sub>app, Mono</sub></italic> values (<italic>PS<sub>Pre, Mono</sub></italic>) and <italic>P<sub>app, Triple</sub></italic> values (<italic>PS<sub>Pre, Triple</sub></italic>). The predicted <italic>PS</italic> values were further compared to their corresponding observations (<italic>PS<sub>obs</sub></italic>). The results showed that the predictive accuracy of <italic>PS<sub>Pre, Triple</sub></italic> was superior to <italic>PS<sub>Pre, Mono</sub></italic>. Except for verapamil, amitriptyline, fluoxetine, and clozapine, the predicted <italic>PS<sub>Pre, Triple</sub></italic> values of the other 14 drugs in the triple co-culture BBB models were within the 0.5- to 2-folds of <italic>PS<sub>obs</sub></italic> (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). However, in the hCMEC/D3 mono-culture BBB model, only seven predicted <italic>PS<sub>Pre, Mono</sub></italic> values were within the 0.5- to 2-folds range of their observations (<xref ref-type="fig" rid="fig7">Figure 7A</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title><italic>In vitro</italic>/<italic>in vivo</italic> correlation assay of blood–brain barrier (BBB) permeability.</title><p>(<bold>A</bold>) The comparison of the estimated permeability coefficient-surface area product (<italic>PS<sub>Pre, Mono</sub></italic>) recalculated from <italic>P<sub>app, Mono</sub></italic> with the observed <italic>in vivo PS</italic> values (<italic>PS<sub>Obs</sub></italic>). (<bold>B</bold>) The comparison of the estimated permeability coefficient-surface area product (<italic>PS<sub>Pre,</sub></italic> <sub><italic>Triple</italic></sub>) recalculated from <italic>P<sub>app, Triple</sub></italic> with the observed <italic>in vivo PS</italic> values (<italic>PS<sub>Obs</sub></italic>). The solid line represents a perfect prediction, and the dashed lines represent the 0.5- to 2-folds of their observations. The <italic>PS<sub>Obs</sub></italic> values were determined by <italic>in situ</italic> brain perfusion in rodents, which were collected from the literature.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig7-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>The unbound fraction in brain (<italic>f<sub>u, brain</sub></italic>), the observed <italic>PS<sub>Obs</sub></italic>, and the predicted <italic>PS</italic> (<italic>PS<sub>Pre</sub></italic>), <italic>P<sub>app</sub></italic> across the hCMEC/D3 mono-culture model (<italic>P<sub>app, Mono</sub></italic>) and triple co-culture model (<italic>P<sub>app, Triple</sub></italic>) of the tested drugs.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>The apparent permeability coefficients of 18 tested drugs from mono- or triple- culture blood–brain barrier (BBB) model.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-96161-table1-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Compounds</th><th align="left" valign="bottom"><italic>f<sub>u, brain</sub></italic></th><th align="left" valign="bottom"><italic>PS<sub>Obs</sub></italic>μl/min/g</th><th align="left" valign="bottom"><italic>P<sub>app, Mono</sub></italic> cm/s × 10<sup>−6</sup></th><th align="left" valign="bottom"><italic>PS<sub>Pre, Mon</sub></italic><sub>o</sub>μl/min/g</th><th align="left" valign="bottom"><italic>P<sub>app, Triple</sub></italic> cm/s × 10<sup>−6</sup></th><th align="left" valign="bottom"><italic>PS<sub>Pre, Triple</sub></italic>μl/min/g</th></tr></thead><tbody><tr><td align="left" valign="bottom">Amantadine</td><td align="char" char="." valign="bottom">0.1985<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="char" char="." valign="bottom">116.10<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">6.84 ± 0.95</td><td align="char" char="." valign="bottom">310.22</td><td align="char" char="plusmn" valign="bottom">3.64 ± 0.26</td><td align="char" char="." valign="bottom">165.23</td></tr><tr><td align="left" valign="bottom">Amitriptyline</td><td align="char" char="." valign="bottom">0.01<sup><xref ref-type="table-fn" rid="table1fn4">‡</xref></sup></td><td align="char" char="." valign="bottom">4608.00<sup><xref ref-type="table-fn" rid="table1fn12">***</xref></sup></td><td align="char" char="plusmn" valign="bottom">15.24 ± 0.64</td><td align="char" char="." valign="bottom">13,716.00</td><td align="char" char="plusmn" valign="bottom">14.61 ± 0.27</td><td align="char" char="." valign="bottom">13,149.00</td></tr><tr><td align="left" valign="bottom">Bupropion</td><td align="char" char="." valign="bottom">0.12<sup><xref ref-type="table-fn" rid="table1fn5">§</xref></sup></td><td align="char" char="." valign="bottom">1519.20<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">15.19 ± 0.20</td><td align="char" char="." valign="bottom">1139.58</td><td align="char" char="plusmn" valign="bottom">11.34 ± 0.44</td><td align="char" char="." valign="bottom">850.58</td></tr><tr><td align="left" valign="bottom">Carbamazepine</td><td align="char" char="." valign="bottom">0.116<sup><xref ref-type="table-fn" rid="table1fn6">¶</xref></sup></td><td align="char" char="." valign="bottom">959.40<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">34.37 ± 1.26</td><td align="char" char="." valign="bottom">2666.89</td><td align="char" char="plusmn" valign="bottom">11.71 ± 0.15</td><td align="char" char="." valign="bottom">908.69</td></tr><tr><td align="left" valign="bottom">Clozapine</td><td align="char" char="." valign="bottom">0.014<sup><xref ref-type="table-fn" rid="table1fn7">**</xref></sup></td><td align="char" char="." valign="bottom">2260.80<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">38.97 ± 0.54</td><td align="char" char="." valign="bottom">25,052.57</td><td align="char" char="plusmn" valign="bottom">12.87 ± 2.06</td><td align="char" char="." valign="bottom">8272.72</td></tr><tr><td align="left" valign="bottom">Donepezil</td><td align="char" char="." valign="bottom">0.07<sup><xref ref-type="table-fn" rid="table1fn8">††</xref></sup></td><td align="char" char="." valign="bottom">1581.30<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">20.91 ± 0.75</td><td align="char" char="." valign="bottom">2688.43</td><td align="char" char="plusmn" valign="bottom">14.47 ± 0.84</td><td align="char" char="." valign="bottom">1860.43</td></tr><tr><td align="left" valign="bottom">Doxepin</td><td align="char" char="." valign="bottom">0.025<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="." valign="bottom">2192.40<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">16.88 ± 1.08</td><td align="char" char="." valign="bottom">6076.80</td><td align="char" char="plusmn" valign="bottom">10.66 ± 0.92</td><td align="char" char="." valign="bottom">3837.60</td></tr><tr><td align="left" valign="bottom">Fluoxetine</td><td align="char" char="." valign="bottom">0.004<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="." valign="bottom">2698.20<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">11.48 ± 0.85</td><td align="char" char="." valign="bottom">25,830.00</td><td align="char" char="plusmn" valign="bottom">9.97 ± 1.03</td><td align="char" char="." valign="bottom">22,430.25</td></tr><tr><td align="left" valign="bottom">Gabapentin</td><td align="char" char="." valign="bottom">0.782<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="." valign="bottom">162.90<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">16.75 ± 1.62</td><td align="char" char="." valign="bottom">192.77</td><td align="char" char="plusmn" valign="bottom">8.78 ± 0.23</td><td align="char" char="." valign="bottom">101.05</td></tr><tr><td align="left" valign="bottom">Lamotrigine</td><td align="char" char="." valign="bottom">0.273<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="." valign="bottom">126.00<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">14.26 ± 0.37</td><td align="char" char="." valign="bottom">470.11</td><td align="char" char="plusmn" valign="bottom">5.97 ± 0.11</td><td align="char" char="." valign="bottom">196.88</td></tr><tr><td align="left" valign="bottom">Metoclopramide</td><td align="char" char="." valign="bottom">0.365<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="." valign="bottom">125.10<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">14.14 ± 1.44</td><td align="char" char="." valign="bottom">348.66</td><td align="char" char="plusmn" valign="bottom">6.63 ± 0.42</td><td align="char" char="." valign="bottom">163.41</td></tr><tr><td align="left" valign="bottom">Midazolam</td><td align="char" char="." valign="bottom">0.045<sup><xref ref-type="table-fn" rid="table1fn9">‡ ‡</xref></sup></td><td align="char" char="." valign="bottom">2727.00<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">25.30 ± 1.00</td><td align="char" char="." valign="bottom">5060.00</td><td align="char" char="plusmn" valign="bottom">19.09 ± 0.24</td><td align="char" char="." valign="bottom">3818.00</td></tr><tr><td align="left" valign="bottom">Mirtazapine</td><td align="char" char="." valign="bottom">0.08<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="." valign="bottom">1912.50<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">23.44 ± 0.44</td><td align="char" char="." valign="bottom">2637.00</td><td align="char" char="plusmn" valign="bottom">17.86 ± 0.21</td><td align="char" char="." valign="bottom">2009.25</td></tr><tr><td align="left" valign="bottom">Olanzapine</td><td align="char" char="." valign="bottom">0.034<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="." valign="bottom">2279.70<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">22.91 ± 3.80</td><td align="char" char="." valign="bottom">6064.41</td><td align="char" char="plusmn" valign="bottom">12.49 ± 0.53</td><td align="char" char="." valign="bottom">3306.18</td></tr><tr><td align="left" valign="bottom">Prazosin</td><td align="char" char="." valign="bottom">0.09<xref ref-type="table-fn" rid="table1fn10"><sup>§ §</sup></xref></td><td align="char" char="." valign="bottom">169.20<xref ref-type="table-fn" rid="table1fn11"><sup>¶ ¶</sup></xref></td><td align="char" char="plusmn" valign="bottom">5.61 ± 0.38</td><td align="char" char="." valign="bottom">560.93</td><td align="char" char="plusmn" valign="bottom">2.81 ± 0.52</td><td align="char" char="." valign="bottom">280.99</td></tr><tr><td align="left" valign="bottom">Risperidone</td><td align="char" char="." valign="bottom">0.099<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="." valign="bottom">849.60<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">16.10 ± 2.87</td><td align="char" char="." valign="bottom">1463.64</td><td align="char" char="plusmn" valign="bottom">11.70 ± 0.25</td><td align="char" char="." valign="bottom">1063.64</td></tr><tr><td align="left" valign="bottom">Venlafaxine</td><td align="char" char="." valign="bottom">0.205<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="char" char="." valign="bottom">584.10<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="bottom">9.58 ± 0.28</td><td align="char" char="." valign="bottom">420.60</td><td align="char" char="plusmn" valign="bottom">8.25 ± 0.36</td><td align="char" char="." valign="bottom">362.02</td></tr><tr><td align="left" valign="bottom">Verapamil</td><td align="char" char="." valign="bottom">0.033 <sup><xref ref-type="table-fn" rid="table1fn4">‡</xref></sup></td><td align="char" char="." valign="bottom">335.70 <sup><xref ref-type="table-fn" rid="table1fn4">‡</xref></sup></td><td align="char" char="plusmn" valign="bottom">7.21 ± 0.41</td><td align="char" char="." valign="bottom">1965.24</td><td align="char" char="plusmn" valign="bottom">5.56 ± 0.06</td><td align="char" char="." valign="bottom">1517.67</td></tr></tbody></table><table-wrap-foot><fn><p>One technical replicate of four biological replicates per group.</p></fn><fn id="table1fn2"><label>*</label><p>(<xref ref-type="bibr" rid="bib23">Esaki et al., 2019</xref>).</p></fn><fn id="table1fn3"><label>†</label><p>(<xref ref-type="bibr" rid="bib73">Summerfield et al., 2007</xref>).</p></fn><fn id="table1fn4"><label>‡</label><p>(<xref ref-type="bibr" rid="bib26">Fridén et al., 2011</xref>).</p></fn><fn id="table1fn5"><label>§</label><p>(<xref ref-type="bibr" rid="bib9">Bhattacharya et al., 2021</xref>).</p></fn><fn id="table1fn6"><label>¶</label><p>(<xref ref-type="bibr" rid="bib52">Maurer et al., 2005</xref>).</p></fn><fn id="table1fn7"><label>**</label><p>(<xref ref-type="bibr" rid="bib16">Cremers et al., 2012</xref>).</p></fn><fn id="table1fn8"><label>††</label><p>(<xref ref-type="bibr" rid="bib18">Di et al., 2011</xref>).</p></fn><fn id="table1fn9"><label>‡ ‡</label><p>(<xref ref-type="bibr" rid="bib38">Kodaira et al., 2011</xref>).</p></fn><fn id="table1fn10"><label>§ §</label><p>(<xref ref-type="bibr" rid="bib88">Zhou et al., 2009</xref>).</p></fn><fn id="table1fn11"><label>¶ ¶</label><p>(<xref ref-type="bibr" rid="bib20">Di Marco et al., 2019</xref>).</p></fn><fn id="table1fn12"><label>***</label><p>(<xref ref-type="bibr" rid="bib4">Avdeef and Sun, 2011</xref>).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The main findings of the study were to successfully develop an <italic>in vitro</italic> triple co-culture BBB model consisting of hCMEC/D3, U251, and SH-SY5Y cells and to confirm the involvement of neurons in BBB maintenance as well as the possible mechanisms. Co-culture with U251 and/or SH-SY5Y cells markedly promoted the TEER of hCMEC/D3 cells and reduced the leakage of fluorescein and FITC-Dex due to the upregulation of claudin-5 and VE-cadherin expression.</p><p>The roles of claudin-5 and VE-cadherin in the maintenance of BBB function have been demonstrated (<xref ref-type="bibr" rid="bib17">Dejana et al., 2008</xref>; <xref ref-type="bibr" rid="bib29">Hashimoto et al., 2023</xref>; <xref ref-type="bibr" rid="bib42">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Ohtsuki et al., 2007</xref>). It was reported that <italic>Cld-5</italic>-deficient mice exhibited BBB impairment, allowing the transport of small molecules (&lt;800 D) across BBB (<xref ref-type="bibr" rid="bib56">Nitta et al., 2003</xref>). In contrast, claudin-5 overexpression significantly restricted the permeability of inulin across the conditionally immortalized rat brain capillary endothelial cell monolayer (<xref ref-type="bibr" rid="bib58">Ohtsuki et al., 2007</xref>). Moreover, the claudin-5 expression in hCMEC/D3 is much lower than in human brain microvessels (<xref ref-type="bibr" rid="bib22">Eigenmann et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Ohtsuki et al., 2013</xref>; <xref ref-type="bibr" rid="bib83">Weksler et al., 2013</xref>), which may cause the low TEER values. VE-cadherin, a major member of the cadherin family in endothelial cells, is also required for BBB integrity (<xref ref-type="bibr" rid="bib17">Dejana et al., 2008</xref>; <xref ref-type="bibr" rid="bib42">Li et al., 2018</xref>). The absence of VE-cadherin resulted in faulty cell-to-cell junctions and disrupted distribution of ZO-1 (<xref ref-type="bibr" rid="bib67">Sauteur et al., 2017</xref>; <xref ref-type="bibr" rid="bib78">Tunggal et al., 2005</xref>). Strongly negative correlations between <italic>P<sub>app</sub></italic> values of fluorescein or FITC-Dex and expression of claudin-5 or VE-cadherin further demonstrated the importance of claudin-5 and VE-cadherin in BBB integrity.</p><p>Neurons and astrocytes, as important components of the NVU, may be involved in the formation and maintenance of BBB function. Several reports showed that co-culture with astrocytes CC-2565 or SC-1810 enhanced the TEER of hCMEC/D3 cells (<xref ref-type="bibr" rid="bib30">Hatherell et al., 2011</xref>), whereas co-culture of RBE4.B cells with primary rat neurons and astrocytes showed a lower permeability of [<sup>3</sup>H] sucrose than mono-culture of RBE4.B cells (<xref ref-type="bibr" rid="bib70">Schiera et al., 2005</xref>). Similarly, co-cultured with hCMEC/D3 cells and 1321N1 (astrocytes) or 1321N1+SH-SY5Y cells possess higher TEER values and lower permeability to Lucifer yellow than hCMEC/D3 alone. Compared with double co-culture of hCMEC/D3 and 321N1 cells, the triple co-culture of hCMEC/D3, 1321N1, and SH-SY5Y cells showed higher TEER values (<xref ref-type="bibr" rid="bib6">Barberio et al., 2022</xref>). Our study also demonstrated that co-culture with U251 and/or SH-SY5Y cells significantly lowered BBB permeability and upregulated VE-cadherin or claudin-5 expression in hCMEC/D3 cells.</p><p>Next, we focused on the molecular mechanisms by which neurons and possibly astrocytes upregulated the VE-cadherin and claudin-5 expression in BMECs. Co-culture with SH-SY5Y cells significantly upregulated claudin-5 and VE-cadherin expression in hCMEC/D3 cells. In the double co-culture with SH-SY5Y cells or triple co-culture BBB models, hCMEC/D3 cells were not in direct contact with SH-SY5Y cells, indicating that the interaction between SH-SY5Y and hCMEC/D3 cells depended on the release of some active compounds. It was consistent with the above deduction that the S-CM also markedly induced claudin-5 and VE-cadherin expression. Different from S-CM, U-CM mainly upregulated the VE-cadherin expression and just had a slight impact on claudin-5. In general, neurons but also astrocytes secrete some neurotrophic factors (<xref ref-type="bibr" rid="bib49">Lonka-Nevalaita et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Sweeney et al., 2019</xref>) that could contribute to the maintenance of structural stability of BBB. High levels of bFGF, GDNF, IGF-1, and TGF-<italic>β</italic> were detected in U-CM, S-CM, and US-CM. Further research showed that only GDNF-induced VE-cadherin and claudin-5 expression in hCMEC/D3 cells in a concentration-dependent manner, and the anti-GDNF antibody attenuated claudin-5 and VE-cadherin expression induced by US-CM or GDNF. These results indicated that neurons upregulated claudin-5 and VE-cadherin expression through GDNF secretion. Levels of GDNF in S-CM were higher than those in U-CM, which seemed to partly explain why S-CM has a stronger promoting effect on claudin-5 than U-CM. The roles of GDNF in BBB maintenance and the regulation of claudin-5 and VE-cadherin expression were further confirmed using brain-specific <italic>Gdnf</italic> knockdown C57BL/6J mice. Consistent with our <italic>in vitro</italic> results, brain-specific <italic>Gdnf</italic> silencing greatly increased BBB penetration of fluorescein and FITC-Dex, accompanied by the downregulation of claudin-5 and VE-cadherin expression.</p><p>GDNF is mainly expressed in astrocytes and neurons (<xref ref-type="bibr" rid="bib49">Lonka-Nevalaita et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Pochon et al., 1997</xref>). In adult animals, GDNF is mainly secreted by striatal neurons rather than astrocytes and microglial cells (<xref ref-type="bibr" rid="bib32">Hidalgo-Figueroa et al., 2012</xref>). The present study also shows that GDNF mRNA levels in SH-SY5Y cells were significantly higher than that in U251 cells. GDNF was also detected in CM from SH-SY5Y cells. All these results demonstrate that neurons may secrete GDNF.</p><p>Generally, GDNF activates several signal transduction pathways, such as the PI3K/AKT and MAPK signaling pathways (<xref ref-type="bibr" rid="bib25">Fielder et al., 2018</xref>) by forming a heterohexameric complex with two GFR<italic>α</italic> molecules and RET receptors. It was also reported that GDNF improved BBB barrier function due to the activation of MAPK/ERK1 (<xref ref-type="bibr" rid="bib21">Dong and Ubogu, 2018</xref>) and PI3K/AKT (<xref ref-type="bibr" rid="bib48">Liu et al., 2022</xref>) signaling. Consistent with previous reports, we found that signaling inhibitors SPP-86, PP2, LY294002, and U0126 markedly attenuated US-CM- and GDNF-induced claudin-5 and VE-cadherin expression in hCMEC/D3 cells, inferring that GDNF promoted claudin-5 and VE-cadherin expression via activating both the PI3K/AKT and MAPK/ERK pathways.</p><p>Signal transduction pathways control gene expression by modifying the function of nuclear transcription factors. The nuclear accumulation of FOXO1 negatively regulates claudin-5 expression (<xref ref-type="bibr" rid="bib7">Beard et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Taddei et al., 2008</xref>). FOXO1 is an important target of the PI3K/AKT signaling axis (<xref ref-type="bibr" rid="bib87">Zhang et al., 2011</xref>), and AKT-induced phosphorylation of FOXO1 results in cytoplasmic FOXO1 accumulation and decreases nuclear FOXO1 accumulation (<xref ref-type="bibr" rid="bib87">Zhang et al., 2011</xref>). From these results, we inferred that GDNF-induced claudin-5 expression in hCMEC/D3 cells may be involved in the activation of PI3K/AKT/FOXO1 pathway. Similarly, both US-CM and GDNF increased cytoplasmic p-FOXO1 and decreased nuclear FOXO1 in hCMEC/D3 cells, which was reversed by LY29002 rather than U0126. Roles of FOXO1 in GDNF-induced claudin-5 were verified through silencing and overexpressing <italic>FOXO1</italic> in hCMEC/D3 cells. <italic>FOXO1</italic> silencing enhanced claudin-5 but not VE-cadherin expression, accompanied by a decline in total and nuclear FOXO1. In contrast, <italic>FOXO1</italic> overexpression significantly decreased claudin-5 expression. In hCMEC/D3 cells overexpressing <italic>FOXO1</italic>, GDNF lost its promotion effect on claudin-5 expression. It was noticed that U0126 attenuated the GDNF-induced upregulation of claudin-5 but had minimal impact on GDNF-mediated FOXO1 phosphorylation and the decline of nuclear FOXO1. In Sertoli cells, it was found that testosterone-stimulated claudin-5 expression by activating the RAS/RAF/ERK/CREB pathway (<xref ref-type="bibr" rid="bib13">Bulldan et al., 2016</xref>). The transcriptional regulation of claudin-5 by CREB was confirmed in bEnd.3 (mouse brain endothelial cell). CREB overexpression significantly increased both gene and protein expression of claudin-5. In contrast, depletion of CREB decreased claudin-5 expression in gene and protein levels (<xref ref-type="bibr" rid="bib43">Li et al., 2022a</xref>). However, another report showed that in human lung microvascular endothelial cells, U0126 attenuated phosphorylation of ERK and lipopolysaccharide-stimulated claudin-5 damage, indicating activation of MAPK/ERK pathway impaired rather than promoted claudin-5 expression (<xref ref-type="bibr" rid="bib47">Liu et al., 2019</xref>). Thus, the real mechanisms that GDNF-induced activation of the RET/MAPK/ERK pathway promotes claudin-5 expression need further investigation.</p><p>ETS1 is a member of the ETS family that plays an important role in cell adhesion, migration, and blood vessel information. ETS1 binds to an ETS-binding site located in the proximal region of the VE-cadherin promoter, controlling VE-cadherin expression (<xref ref-type="bibr" rid="bib40">Lelièvre, 2001</xref>). Several studies have demonstrated the role of ETS1 in the regulation of VE-cadherin expression. For example, IFN-<italic>γ</italic> and TNF-<italic>α</italic> impaired BBB integrity by decreasing ETS1-induced VE-cadherin expression (<xref ref-type="bibr" rid="bib50">Luo et al., 2022</xref>). <italic>ETS1</italic> silencing reduced VE-cadherin expression in umbilical vein endothelial cells (<xref ref-type="bibr" rid="bib15">Colás-Algora et al., 2020</xref>). In contrast, <italic>ETS1</italic> overexpression induced VE-cadherin expression in mouse brain capillary endothelial cells and fibroblasts (<xref ref-type="bibr" rid="bib39">Lelièvre et al., 2000</xref>). As expected, <italic>ETS1</italic> silencing resulted in a decrease in the expression of VE-cadherin in hCMEC/D3 cells, but claudin-5 expression remained unaffected. Additionally, <italic>ETS1</italic> silencing removed the inductive effect of GDNF on VE-cadherin expression while unaffecting the upregulation of claudin-5 induced by GDNF. The activation of the PI3K/AKT (<xref ref-type="bibr" rid="bib31">He et al., 2023</xref>; <xref ref-type="bibr" rid="bib33">Hui et al., 2018</xref>) and MAPK/ERK (<xref ref-type="bibr" rid="bib80">Watanabe et al., 2004</xref>) pathways promotes ETS1 expression. In our findings, US-CM and GDNF significantly increased total and nuclear ETS1 levels, which were eliminated by signaling inhibitors LY294002 and U0126. Both our results and previous research provide evidence that GDNF upregulates ETS1 expression via the activation of PI3K/AKT and MAPK/ERK signaling to promote VE-cadherin expression.</p><p>Claudin-5 expression is also regulated by VE-cadherin (<xref ref-type="bibr" rid="bib75">Taddei et al., 2008</xref>). Differing from the previous reports, silencing VE-cadherin with siRNA only slightly affected basal and GDNF-induced claudin-5 expression. The discrepancies may come from different characteristics of the tested cells. Several reports have supported the above deduction. In retinal endothelial cells, hyperglycemia remarkably reduced claudin-5 expression (but not VE-cadherin) (<xref ref-type="bibr" rid="bib65">Saker et al., 2014</xref>). However, in hCMEC/D3 cells, hypoglycemia significantly decreased claudin-5 expression but hyperglycemia increased VE-cadherin expression (<xref ref-type="bibr" rid="bib64">Sajja et al., 2014</xref>).</p><p>The present study showed that characteristics of <italic>in vitro</italic> triple co-culture BBB model were superior to those of hCMEC/D3 mono-culture BBB model. The hCMEC/D3 mono-culture and triple co-culture BBB models were used to try to predict the <italic>PS</italic> values of 18 drugs by comparing them with their observations. The prediction success rate (14/18) of triple co-culture BBB model was greater than that of hCMEC/D3 mono-culture BBB model (7/18). However, poor predictions were observed for verapamil, amitriptyline, fluoxetine, and clozapine, which may partly be due to inaccuracies in their <italic>f<sub>u, brain</sub></italic> values. These four drugs are high protein-binding drugs. Due to the methodological discordance and limitations of historic devices for these drugs, the <italic>f<sub>u</sub></italic> ≤ 0.01 maybe with low confidence and accuracy (<xref ref-type="bibr" rid="bib12">Bowman and Benet, 2018</xref>; <xref ref-type="bibr" rid="bib19">Di et al., 2017</xref>). For example, <italic>f<sub>u, brain</sub></italic> values of amitriptyline from different reports display large differences [0.002 (<xref ref-type="bibr" rid="bib66">Sánchez-Dengra et al., 2021</xref>), 0.0071 (<xref ref-type="bibr" rid="bib82">Weber et al., 2013</xref>)]. The same large differences of <italic>f<sub>u, brain</sub></italic> values were also found in fluoxetine [0.0023 (<xref ref-type="bibr" rid="bib52">Maurer et al., 2005</xref>), 0.004 (<xref ref-type="bibr" rid="bib73">Summerfield et al., 2007</xref>), 0.00094 (<xref ref-type="bibr" rid="bib46">Liu et al., 2005</xref>)], and clozapine [0.0056 (<xref ref-type="bibr" rid="bib10">Bhyrapuneni et al., 2018</xref>), 0.014 (<xref ref-type="bibr" rid="bib16">Cremers et al., 2012</xref>), 0.011 (<xref ref-type="bibr" rid="bib73">Summerfield et al., 2007</xref>)].</p><p>In summary, our triple co-culture BBB model outperformed the mono-culture or double co-culture BBB models, mainly attributing to the fact that neurons and possibly astrocytes upregulated claudin-5 and VE-cadherin expression by secreting GDNF through activating PI3K/AKT and MAPK/ERK pathways. Additionally, the developed <italic>in vitro</italic> triple co-culture BBB model accurately predicted the <italic>in vivo</italic> BBB permeability of CNS drugs. This suggests the potential of our triple co-culture BBB model for utilization in CNS candidate screening during the drug development process (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>The mechanism of neurons and astrocytes induced the integrity of brain endothelial cells.</title><p>Neurons but also astrocytes trigger the activation of PI3K/AKT and MAPK/ERK pathways in brain endothelial cells by glial cell line-derived neurotrophic factor (GDNF) secretion, which in turn regulates transcription factors of claudin-5 (FOXO1) and VE-cadherin (ETS1) to promote claudin-5 and VE-cadherin expression and leads to the enhancement of blood–brain barrier (BBB) integrity. Meanwhile, with the increase in barrier integrity, the <italic>in vitro</italic> BBB model also obtained a stronger <italic>in vivo</italic> correlation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig8-v1.tif"/></fig><p>However, the study also has some limitations. In addition to neurons and astrocytes, other cells such as microglia, pericytes, and vascular smooth muscle cells, especially pericytes, may also affect BBB function. How pericytes affect BBB function and interaction among neurons, astrocytes, and pericytes needs further investigation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom"><italic>β</italic>-Actin<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">66009<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2883475">AB_2883475</ext-link></td><td align="char" char="." valign="bottom">1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">GAPDH<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Absin</td><td align="left" valign="bottom">Abs830030ss<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2811228">AB_2811228</ext-link></td><td align="char" char="." valign="bottom">1:50,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom"><italic>β</italic>-Tubulin<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Fdbio Science</td><td align="left" valign="bottom">FD0064<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3076327">AB_3076327</ext-link></td><td align="char" char="." valign="bottom">1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Lamin B<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">66095<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2721256">AB_2721256</ext-link></td><td align="char" char="." valign="bottom">1:10,000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Claudin-5<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Wanleibio</td><td align="left" valign="bottom">WL03731<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3076320">AB_3076320</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Occludin<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Wanleibio</td><td align="left" valign="bottom">WL01996<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3076325">AB_3076325</ext-link></td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ZO-1<break/>(mouse polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">21773-1-AP<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10733242">AB_10733242</ext-link></td><td align="char" char="." valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">VE-cadherin<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Wanleibio</td><td align="left" valign="bottom">WL02033<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3076321">AB_3076321</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom"><italic>β</italic>-Catenin<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Wanleibio</td><td align="left" valign="bottom">WL0962a<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3076323">AB_3076323</ext-link></td><td align="char" char="." valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BCPR<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">4477S<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10544928">AB_10544928</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P-gp<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">13978S<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2798357">AB_2798357</ext-link></td><td align="char" char="." valign="bottom">1:1500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p-AKT<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Huaan Biotechnology</td><td align="left" valign="bottom">ET1607<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2940863">AB_2940863</ext-link></td><td align="char" char="." valign="bottom">1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">AKT<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Huaan Biotechnology</td><td align="left" valign="bottom">ET1609<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3069857">AB_3069857</ext-link></td><td align="char" char="." valign="bottom">1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p-ERK<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">28733-1-AP<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2881202">AB_2881202</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ERK<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">11257-1-AP<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2139822">AB_2139822</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p-p38<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">4511S<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10890701">AB_10890701</ext-link></td><td align="char" char="." valign="bottom">1:250</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p38<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">8690S<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10999090">AB_10999090</ext-link></td><td align="char" char="." valign="bottom">1:250</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p-JNK<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Wanleibio</td><td align="left" valign="bottom">WL01813<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2910628">AB_2910628</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">JNK<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Wanleibio</td><td align="left" valign="bottom">WL01295<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3064853">AB_3064853</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FOXO1<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">18592<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2934932">AB_2934932</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p-FOXO1<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Wanleibio</td><td align="left" valign="bottom">WL03634<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3076326">AB_3076326</ext-link></td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ETS1<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">sc-55581<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_831289">AB_831289</ext-link></td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ETS1<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">66598<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2881958">AB_2881958</ext-link></td><td align="char" char="." valign="bottom">1:3000</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">hCMEC/D3 cells</td><td align="left" valign="bottom">JENNIO<break/>Biological Technology, Guangzhou, China</td><td align="left" valign="bottom">Cat#JNO-H0520<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_U985">CVCL_U985</ext-link></td><td align="left" valign="bottom">Authenticated<break/>(STR profiling)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">U251 cells</td><td align="left" valign="bottom">Cellcook Biological Technology, Guangzhou, China</td><td align="left" valign="bottom">Cat#CC1701<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0021">CVCL_0021</ext-link></td><td align="left" valign="bottom">Authenticated<break/>(STR profiling)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">SH-SY5Y cells</td><td align="left" valign="bottom">Cellcook Biological Technology, Guangzhou, China</td><td align="left" valign="bottom">Cat#CC2101<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0019">CVCL_0019</ext-link></td><td align="left" valign="bottom">Authenticated<break/>(STR profiling)</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">Version 8.0.2</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">BioTek Cytation 5 Cell Imaging Multi-Mode Reader</td><td align="left" valign="bottom">BioTek Cytation 5</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_019732">SCR_019732</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">QuantStudio 3 Real Time PCR System</td><td align="left" valign="bottom">QuantStudio 3</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018712">SCR_018712</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FACS Celesta Flow Cytometer</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_019597">SCR_019597</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Flowjo software</td><td align="left" valign="bottom">Version 10.4</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">GDNF-Elisa kit</td><td align="left" valign="bottom">R&amp;D system<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006140">SCR_006140</ext-link></td><td align="left" valign="bottom">Cat#212-GD</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">bFGF-Elisa kit</td><td align="left" valign="bottom">Elabscience<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025982">SCR_025982</ext-link></td><td align="left" valign="bottom">Cat#E-EL-H6042</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">IGF-1-Elisa kit</td><td align="left" valign="bottom">Elabscience<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025982">SCR_025982</ext-link></td><td align="left" valign="bottom">Cat#E-EL-H0086</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TGF-<italic>β</italic>-Elisa kit</td><td align="left" valign="bottom">Elabscience<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025982">SCR_025982</ext-link></td><td align="left" valign="bottom">Cat#E-EL-0162</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">GDNF</td><td align="left" valign="bottom">R&amp;D system<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006140">SCR_006140</ext-link></td><td align="left" valign="bottom">Cat#212-GD</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">bFGF</td><td align="left" valign="bottom">MedChemExpress<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025062">SCR_025062</ext-link></td><td align="left" valign="bottom">Cat#HY-P7331</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">IGF-1</td><td align="left" valign="bottom">MedChemExpress<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025062">SCR_025062</ext-link></td><td align="left" valign="bottom">Cat#HY-P70783</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">TGF-<italic>β</italic></td><td align="left" valign="bottom">MedChemExpress<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025062">SCR_025062</ext-link></td><td align="left" valign="bottom">Cat#HY-P70543</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SPP-86</td><td align="left" valign="bottom">MedChemExpress<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025062">SCR_025062</ext-link></td><td align="left" valign="bottom">Cat#HY-110193</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PP2</td><td align="left" valign="bottom">MedChemExpress<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025062">SCR_025062</ext-link></td><td align="left" valign="bottom">Cat#HY-13805</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">LY294002</td><td align="left" valign="bottom">MedChemExpress<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025062">SCR_025062</ext-link></td><td align="left" valign="bottom">Cat#HY-10108</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">U0126</td><td align="left" valign="bottom">MedChemExpress<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025062">SCR_025062</ext-link></td><td align="left" valign="bottom">Cat#S1102</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SP600125</td><td align="left" valign="bottom">Selleck<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003823">SCR_003823</ext-link></td><td align="left" valign="bottom">Cat#HY-12041</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SB203580</td><td align="left" valign="bottom">MedChemExpress<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_025062">SCR_025062</ext-link></td><td align="left" valign="bottom">Cat#HY-10256</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture and viability assay</title><p>Rat BMECs were isolated from Sprague-Dawley rats (male, 7–10 days old, Sino-British Sippr/BKLaboratory Animal Ltd, Shanghai, China) as the described method (<xref ref-type="bibr" rid="bib36">Ji et al., 2013</xref>; <xref ref-type="bibr" rid="bib41">Li et al., 2013</xref>) and cultured in Dulbecco’s Modified Eagle Media (DMEM)/F12 (#12500-039, Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS) (#10100147C, Gibco, Carlsbad, CA, USA) and 62.5 µg/ml penicillin and 100 µg/ml streptomycin (SunShine Biotechnology Co., Ltd, Nanjing, China). Then, hCMEC/D3, U251, and SH-SY5Y cells were cultured in DMEM/F12 containing 10% FBS, 62.5 µg/ml penicillin and 100 µg/ml streptomycin. Cell viability was assessed using a CCK-8 kit (Beyotime Biotechnology, Shanghai, China), and the results were expressed as the fold of control.</p></sec><sec id="s4-2"><title>Establishment of the triple co-culture model</title><p>Although hCMEC/D3 cells have poor barrier properties and low TEER compared to human physiological BBB, the use of human BMECs may be restricted by the acquisition of materials and ethical approval. Isolation and purification of primary BMECs are time-consuming and laborious. Moreover, culture conditions can alter transcriptional activity (<xref ref-type="bibr" rid="bib63">Qi et al., 2023</xref>). All limit the establishment of BBB models based on primary human BMECs for high-throughput screening. Here, hCMEC/D3 cells were selected to establish an <italic>in vitro</italic> BBB model.</p><p>The establishment process of the triple co-culture model is illustrated in <xref ref-type="fig" rid="fig9">Figure 9</xref>. SH-SY5Y cells were seeded at a density of 4.5 × 10<sup>4</sup> cells/cm<sup>2</sup> in plates and differentiated with 10 μM retinoic acid (Sigma-Aldrich, St. Louis, MO, USA) for 72 hr. The differentiated SH-SY5Y cells were cultured in the fresh DMEM/F12 medium containing 10% FBS. U251 cells were seeded at 2 × 10<sup>4</sup> cells/cm<sup>2</sup> on the bottom of Transwell inserts (PET, 0.4 µm pore size, SPL Life Sciences, Pocheon, Korea) coated with rat-tail collagen (Corning Inc, Corning, NY, USA). Next, the inserts were suspended in plate wells containing the culture medium after 5 hr of incubation. After 24 hr of incubation, hCMEC/D3 cells were seeded on the apical side of the inserts at 3 × 10<sup>4</sup> cells/cm<sup>2</sup> and cultured for another 48 hr. Then, the inserts seeded with U251 and hCMEC/D3 cells were suspended in plates seeded with differentiated SH-SY5Y cells and co-cultured for another 6 days. The culture medium was replaced every 24 hr. TEER was periodically measured using a Millicell-ERS (MERS00002) instrument (Millipore, Billerica MA, USA) to monitor cell confluence and development of TJs.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Schematic diagram of the establishment process of the triple co-culture blood–brain barrier (BBB) model.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96161-fig9-v1.tif"/></fig></sec><sec id="s4-3"><title>EdU incorporation assay</title><p>The cells were incubated with medium containing 10 μM Edu for 2 hr. Then cells were washed by phosphate-buffered saline (PBS) and harvested by 0.25% trypsin–ethylenediaminetetraacetic acid (#25200072, Gibco, Carlsbad, CA, USA). The EdU incorporation assay was measured using the BeyoClick EdU Cell Proliferation Kit (Beyotime Biotechnology, Shanghai, China) according to the manufacturer’s instructions. The samples were determined on the FACSCelesta flow cytometer (Becton, Dickins on and Company, USA), and data were analyzed by Flowjo 10.4 software.</p></sec><sec id="s4-4"><title><italic>In vitro</italic> BBB permeability study</title><p>On day 7, the TEER values of BBB models showed a decreasing trend. Therefore, the subsequent experiments were all completed on day 6. The culture medium was removed from the apical and basolateral sides of the inserts and washed twice with preheated Hank’s balanced salt solution (HBSS). Fresh HBSS was then added to both the apical and basolateral chambers. After 15 min of preincubation, HBSS in the apical and basolateral chambers was replaced with HBSS containing FITC-dextran 3–5 kDa (FITC-Dex) (Sigma-Aldrich, St. Louis, MO, USA), fluorescein sodium (Sigma-Aldrich, St. Louis, MO, USA), or other tested agents and blank HBSS, respectively. Next, 200 μl aliquots were collected from the basolateral chamber after 30 min of incubation at 37°C. The concentrations of the tested agents in the basolateral chamber were measured.</p><p>The apparent permeability coefficient (<italic>P<sub>app</sub></italic>, cm/s) values of the tested agents across the <italic>in vitro</italic> BBB model were calculated using the equation (<xref ref-type="bibr" rid="bib77">Tavelin et al., 2002</xref>):<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow></mml:mrow><mml:mtext>1800</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>S</mml:mi><mml:mo>×</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where <italic>S</italic> is the surface area of the insert membrane (0.33 cm<sup>2</sup> for 6.5 mm inserts, 4.46 cm<sup>2</sup> for 24 mm inserts), <italic>Q</italic> is the transported amount of the tested agents transported from the donor chamber to the receiver chamber for 30 min (1800 s), and <italic>C<sub>0</sub></italic> is the initial concentration of the tested agents in the donor chamber.</p></sec><sec id="s4-5"><title>The quantification methods of prazosin, verapamil, lamotrigine</title><p>Prazosin, verapamil, and lamotrigine (Aladdin, Shanghai, China) were analyzed by high-performance liquid chromatography (Shimadzu, Kyoto, Japan) with YMC-Triart C18 column (5 μm, 150 × 4.6 mm, YMC America Inc, Allentown, PA, USA). Prazosin and verapamil were detected using the RF-20A fluorescence detector. Lamotrigine was detected using the SPD-20A ultraviolet detector. Samples were centrifugated at 12,000 rpm for 10 min, then 150 μl supernatant was taken and used for analysis. The run temperature was set at 40°C, the injection volume was 20 μl and the flow rate was 1 ml/min. Initial concentrations in donor chamber and other chromatographic conditions of drugs are summarized in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Initial concentrations in donor chamber and chromatographic conditions of prazosin, verapamil, and lamotrigine.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Compound</th><th align="left" valign="bottom">Concentration (μM)</th><th align="left" valign="bottom">Wavelength (nm)</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2">Prazosin</td><td align="char" char="." valign="bottom" rowspan="2">5</td><td align="left" valign="bottom">Ex: 250</td></tr><tr><td align="left" valign="bottom">Em: 390</td></tr><tr><td align="left" valign="bottom" rowspan="2">Verapamil</td><td align="char" char="." valign="bottom" rowspan="2">5</td><td align="left" valign="bottom">Ex: 280</td></tr><tr><td align="left" valign="bottom">Em: 310</td></tr><tr><td align="left" valign="bottom">Lamotrigine</td><td align="char" char="." valign="bottom">6</td><td align="char" char="." valign="bottom">220</td></tr></tbody></table></table-wrap></sec><sec id="s4-6"><title>The quantification methods of clozapine, venlafaxine, bupropion, amantadine, carbamazepine, fluoxetine, amitriptyline, gabapentin, midazolam, risperidone, olanzapine, mirtazapine, metoclopramide, doxepin, donepezil</title><p>All compounds were purchased from Aladdin (Shanghai, China). Except for prazosin, verapamil, and lamotrigine, the other compounds were analyzed by using liquid chromatography–mass spectrometry (Shimadzu, Kyoto, Japan) with YMC-Triart C18 column (5 μm, 150 × 2.0 mm, YMC America Inc, Allentown, PA, USA). Each sample was mixed with 10 µl internal standard. Then 1 ml extraction was added to each sample. The samples were vortex vibrated on the oscillator for 10 min, and then centrifuged at 4°C and 12,000 rpm for 10 min. The supernatant solvent was evaporated with nitrogen flow, then redissolved with 100 µl 40% (vol/vol) acetonitrile, and centrifuged at 4°C and 15,000 rpm for 10 min. The supernatants were injected into LC–MS for analysis. The injection volume of each sample was 5 µl. The mass charge ratio, extraction, and initial concentrations in donor chamber of drugs are summarized in <xref ref-type="table" rid="table3">Table 3</xref>.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>The summary of mass charge ratio, extraction, initial concentrations in donor chamber.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Compound</th><th align="left" valign="bottom">Concentration (μM)</th><th align="left" valign="bottom">Mass charge ratio[M+H]<sup>+</sup></th><th align="left" valign="bottom">Extraction</th></tr></thead><tbody><tr><td align="left" valign="bottom">Amantadine</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">181</td><td align="left" valign="bottom">Water-saturated <italic>N</italic>-butanol</td></tr><tr><td align="left" valign="bottom">Amitriptyline</td><td align="char" char="." valign="bottom">1.5</td><td align="char" char="." valign="bottom">278</td><td align="left" valign="bottom">Ethyl acetate</td></tr><tr><td align="left" valign="bottom">Bupropion</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">240</td><td align="left" valign="bottom">Ethyl acetate</td></tr><tr><td align="left" valign="bottom">Carbamazepine</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">237</td><td align="left" valign="bottom">Ethyl acetate</td></tr><tr><td align="left" valign="bottom">Clozapine</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">327</td><td align="left" valign="bottom">Ethyl acetate</td></tr><tr><td align="left" valign="bottom">Donepezil</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">380</td><td align="left" valign="bottom">Methyl tert-butyl ether</td></tr><tr><td align="left" valign="bottom">Doxepin</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">317</td><td align="left" valign="bottom">Methyl tert-butyl ether</td></tr><tr><td align="left" valign="bottom">Fluoxetine</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">310</td><td align="left" valign="bottom">Ethyl acetate</td></tr><tr><td align="left" valign="bottom">Gabapentin</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">172</td><td align="left" valign="bottom">Ethyl acetate</td></tr><tr><td align="left" valign="bottom">Metoclopramide</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">301</td><td align="left" valign="bottom">Ethyl acetate</td></tr><tr><td align="left" valign="bottom">Midazolam</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">327</td><td align="left" valign="bottom">Ethyl acetate</td></tr><tr><td align="left" valign="bottom">Mirtazapine</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">266</td><td align="left" valign="bottom">Methyl tert-butyl ether</td></tr><tr><td align="left" valign="bottom">Olanzapine</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">313</td><td align="left" valign="bottom">Methyl tert-butyl ether</td></tr><tr><td align="left" valign="bottom">Risperidone</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">427</td><td align="left" valign="bottom">Methyl tert-butyl ether</td></tr><tr><td align="left" valign="bottom">Venlafaxine</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">278</td><td align="left" valign="bottom">Ethyl acetate</td></tr></tbody></table></table-wrap></sec><sec id="s4-7"><title>Cell density analysis</title><p>On day 6 of co-culture, hCMEC/D3 cells were fixed with 4% paraformaldehyde for 15 min and washed with PBS for three times. Next, the fixed cells were blocked with 5% goat serum for 2 hr and washed with PBS for four times. The blocked cells were incubated with 4’,6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA, USA) and washed with PBS for four times. Cell numbers were counted using Cytation5 (BioTek, Winooski, VT, USA).</p></sec><sec id="s4-8"><title>Reverse transcription and qPCR</title><p>Total RNA of cells was extracted using RNAiso Plus reagent (Takara Bio Inc, Otsu, Shiga, Japan) and reverse transcribed using HiScript III RT SuperMix (Vazyme, Shanghai, China) as the described method (<xref ref-type="bibr" rid="bib86">Yang et al., 2023</xref>). Paired primers were synthesized by Tsingke Biotech Co., Ltd (Beijing, China), and their sequences are listed in <xref ref-type="table" rid="table4">Table 4</xref>. The SYBR Master Mix was purchased from Yeasen (Shanghai, China). Then, qPCR was performed on the Applied Biosystems QuantStudio 3 real-time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The mRNA levels of related genes were normalized to <italic>ACTB</italic> or <italic>GAPDH</italic> using the comparative cycle threshold method.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Primer sequences for quantitative real-time PCR (qPCR) for indicted genes.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene (protein)</th><th align="left" valign="bottom">Forwards primer, 5′→3′</th><th align="left" valign="bottom">Reverse primer, 3′→5′</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>ACTB</italic> (<italic>β</italic>-actin)</td><td align="left" valign="bottom"><named-content content-type="sequence">GGACTTCGAGCAAGAGATGG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGCACTGTGTTGGCGTACAG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>GAPDH</italic> (GAPDH)</td><td align="left" valign="bottom"><named-content content-type="sequence">TGTGGGCATCAATGGATTTGG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">ACACCATGTATTCCGGGTCAAT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>CLDN5</italic> (claudin-5)</td><td align="left" valign="bottom"><named-content content-type="sequence">CTCTGCTGGTTCGCCAACAT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CAGCTCGTACTTCTGCGACA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>OCLN</italic> (occludin)</td><td align="left" valign="bottom"><named-content content-type="sequence">ACAAGCGGTTTTATCCAGAGTC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GTCATCCACAGGCGAAGTTAAT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>TJP1</italic> (ZO-1)</td><td align="left" valign="bottom"><named-content content-type="sequence">ACCAGTAAGTCGTCCTGATCC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TCGGCCAAATCTTCTCACTCC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>CDH5</italic> (VE-cadherin)</td><td align="left" valign="bottom"><named-content content-type="sequence">AAGCGTGAGTCGCAAGAATG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TCTCCAGGTTTTCGCCAGTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>ABCB1</italic> (P-gp)</td><td align="left" valign="bottom"><named-content content-type="sequence">TTGCTGCTTACATTCAGGTTTCA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGCCTATCTCCTGTCGCATTA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>ABCG2</italic> (BCRP)</td><td align="left" valign="bottom"><named-content content-type="sequence">ACGAACGGATTAACAGGGTCA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CTCCAGACACACCACGGAT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>SLC22A1</italic> (OCT1)</td><td align="left" valign="bottom"><named-content content-type="sequence">ACGGTGGCGATCATGTACC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCCATTCTTTTGAGCGATGTGG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>SLC22A2</italic> (OCT2)</td><td align="left" valign="bottom"><named-content content-type="sequence">CATCGTCACCGAGTTTAACCTG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGCCGATACTCATAGAGCCAAT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>SLC22A8</italic> (OAT3)</td><td align="left" valign="bottom"><named-content content-type="sequence">ATGGCCCAGTCTATCTTCATGG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GACGGTGCTCAGGGTAATGC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>SLCO1A1</italic> (OATP1A1)</td><td align="left" valign="bottom"><named-content content-type="sequence">TAATGTGGGTGTACGTCCTAGT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GCTCCTGTTTCTACAAGCCCAA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>GDNF</italic> (GDNF)</td><td align="left" valign="bottom"><named-content content-type="sequence">GCAGACCCATCGCCTTTGAT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCACACCTTTTAGCGGAATGC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>BDNF</italic> (BDNF)</td><td align="left" valign="bottom"><named-content content-type="sequence">CTACGAGACCAAGTGCAATCC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AATCGCCAGCCAATTCTCTTT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>NGF</italic> (NGF)</td><td align="left" valign="bottom"><named-content content-type="sequence">TGTGGGTTGGGGATAAGACCA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GCTGTCAACGGGATTTGGGT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>IGF1</italic> (IGF-1)</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTCTTCAGTTCGTGTGTGGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGTCATGGATGGACCTTACTGT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>VEGFA</italic> (VEGF)</td><td align="left" valign="bottom"><named-content content-type="sequence">CCCACTGAGGAGTCCAACAT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AAATGCTTTCTCCGCTCTGA</named-content></td></tr><tr><td align="left" valign="bottom"><italic>FGF2</italic> (bFGF)</td><td align="left" valign="bottom"><named-content content-type="sequence">AGAAGAGCGACCCTCACATCA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CGGTTAGCACACACTCCTTTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>TGFB1</italic> (TGF-<italic>β</italic>)</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCCAGATCCTGTCCAAGC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GTGGGTTTCCACCATTAGCAC</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-9"><title>Western blotting analysis</title><p>Whole-cell and tissue lysates, nucleoprotein, and cytoplasmic protein were prepared using RIPA Lysis Buffer (Beyotime, Shanghai, China) as the described method (<xref ref-type="bibr" rid="bib84">Wu et al., 2021</xref>). Proteins were separated through sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred onto nitrocellulose or polyvinylidene difluoride membranes. The membranes were blocked with 5% skim milk and incubated with corresponding primary antibodies at 4°C overnight. After being washed with Tris-buffered saline Tween buffer, the membranes were incubated with secondary antibodies (Cell Signaling Technology, MA, USA) at 1:3000 dilution: Anti-mouse IgG, HRP-linked Antibody (#7076), Anti-rabbit IgG, HRP-linked Antibody (#7074). Protein levels were visualized using a highly sensitive ECL western blotting substrate and a gel imaging system (Tanon Science &amp; Technology, Shanghai, China).</p></sec><sec id="s4-10"><title>Preparation of CM</title><p>CM of U251 cells (U-CM), SH-SY5Y cells (S-CM), or co-culture of U251 and SH-SY5Y cells (US-CM) was prepared. U251 cells were seeded at the top of the insert membrane and suspended on 6-well plates seeded with differentiated SH-SY5Y cells to co-culture U251 cells with SH-SY5Y cells. The medium was collected every 24 hr. The CMs were subsequently used for hCMEC/D3 cell culture after filtrating with 0.2 μm filters for 144 hr. The levels of GDNF, bFGF, IGF-1, and TGF-<italic>β</italic> in CMs were measured using corresponding ELISA kits according to the manufacturers’ instructions.</p></sec><sec id="s4-11"><title>Neutralization of GDNF with anti-GDNF antibody</title><p>Exogenous and endogenous GDNF in the medium was neutralized with anti-GDNF antibody (#AF-212-NA, R&amp;D system, Minneapolis, MN, USA). 0.25, 0.5, and 1.0 μg/ml anti-GDNF antibody was added into the US-CM or medium containing 200 pg/ml GDNF, and then the medium was preincubated at 4°C for 1 hr. The hCMEC/D3 cells were incubated with 200 pg/ml GDNF or US-CM containing anti-GDNF antibody or not for 6 days, and then cell lysate was collected for western blot. The medium was replaced every 24 hr.</p></sec><sec id="s4-12"><title>Transfection of hCMEC/D3</title><p>Here, hCMEC/D3 cells were plated in the plates or culture dishes at 6 × 10<sup>4</sup> cells/cm<sup>2</sup> and transfected with 10 nM of negative control or human <italic>FOXO1</italic>, <italic>ETS1,</italic> and <italic>CDH5</italic> siRNA (Tsingke Biotechnology, Beijing, China) for 12 hr using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) reagent according to the manufacturer’s instructions. Cells were then incubated with a medium containing GDNF for 72 hr. The siRNA sequences of human <italic>FOXO1</italic>, <italic>ETS1,</italic> and <italic>CDH5</italic> are summarized in <xref ref-type="table" rid="table5">Table 5</xref>.</p><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>The target sequences for small interfering RNA (siRNA) or short hairpin RNA (shRNA).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene</th><th align="left" valign="bottom">Target sequence</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>ETS1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">CGCTATACCTCGGATTACT</named-content></td></tr><tr><td align="left" valign="bottom"><italic>FOXO1</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">AATCTCCTAGGAGAAGAGCTG</named-content></td></tr><tr><td align="left" valign="bottom"><italic>Gdnf</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GCCAGTGTTTATCTGATAC</named-content></td></tr><tr><td align="left" valign="bottom"><italic>CDH5</italic></td><td align="left" valign="bottom"><named-content content-type="sequence">GCCTCTGTCATGTACCAAA</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-13"><title>FOXO1 overexpression by plasmids</title><p>The plasmids encoding FOXO1 (EX-Z7404-M02) were constructed by GeneCopoeia (Rockville, MD, USA). The hCMEC/D3 cells were plated in plates or dishes at 6 × 10<sup>4</sup> cells/cm<sup>2</sup>. They were subsequently transfected with 1 µg of negative control or plasmids encoding FOXO1 6 hr using Lipofectamine 3000 reagent according to the manufacturer’s instructions. Transfected cells were then incubated with the medium containing GDNF for 72 hr.</p></sec><sec id="s4-14"><title>Animals</title><p>C57BL/6J mice (male, 4–5 weeks old, 16–18 g, 12 mice) were obtained from Sino-British Sippr/BKLaboratory Animal Ltd (Shanghai, China). Mice were maintained in groups under standard conditions with free access to food and water. Animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health) and approved by the Animal Ethics Committee of China Pharmaceutical University (Approval Number: 202307003).</p></sec><sec id="s4-15"><title>Brain-specific <italic>Gdnf</italic> knockdown and evaluation of BBB permeability</title><p>Mice were randomly divided into control (shNC) and <italic>Gdnf</italic> silencing (sh<italic>Gdnf</italic>) groups (6 mice each group). The shRNA sequence of mice <italic>Gdnf</italic> is listed in <xref ref-type="table" rid="table5">Table 5</xref>. The 2 × 10<sup>9</sup> viral genome each of pAAV-U6-shRNA (NC2)-CMV-EGFP or pAAV-U6-shRNA (<italic>Gdnf</italic>)-CMV-EGFP (OBio Technology, Beijing, China) was injected into the bilateral lateral ventricle area (relative to the bregma: anterior–posterior −0.3 mm; medial–lateral ±1.0 mm; dorsal–ventral –3.0 mm) through <italic>i.c.v</italic> infusion. Three weeks following <italic>i.c.v</italic> injection, BBB permeability and expression of corresponding targeted proteins were measured in the mice.</p><p>A mixture of FITC-Dex (50 mg/kg) and fluorescein sodium (10 mg/kg) was intravenously administered to experimental mice. Thirty minutes after the injection, the mice were euthanized under isoflurane anesthesia, and brain tissue and plasma samples were obtained quickly. The concentrations of FITC-Dex and fluorescein in the plasma and brain were measured as previously described (<xref ref-type="bibr" rid="bib44">Li et al., 2022b</xref>; <xref ref-type="bibr" rid="bib89">Zhou et al., 2019</xref>). No blinding was performed in animal studies.</p></sec><sec id="s4-16"><title>The prediction of drug permeability across BBB using the developed <italic>in vitro</italic> BBB model</title><p>The <italic>P<sub>app</sub></italic> values of 18 drugs – prazosin, verapamil, lamotrigine, clozapine, venlafaxine, bupropion, amantadine, carbamazepine, fluoxetine, amitriptyline, gabapentin, midazolam, risperidone, olanzapine, mirtazapine, metoclopramide, doxepin, and donepezil – across the hCMEC/D3 cells mono-culture and triple co-culture models were measured. The predicted <italic>in vivo</italic> permeability-surface area product (<italic>PS<sub>Pre</sub></italic>, μl/min/g brain) values across BBB were calculated using the following equation:<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mtext>=</mml:mtext><mml:mfrac><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mn>60</mml:mn><mml:mo>×</mml:mo><mml:mi>V</mml:mi><mml:mi>S</mml:mi><mml:mi>A</mml:mi><mml:mo>×</mml:mo><mml:mn>1000</mml:mn></mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>b</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>where <italic>VSA</italic> is the luminal area of the vascular space of brain, which was set to 150 cm<sup>2</sup>/g (<xref ref-type="bibr" rid="bib24">Fenstermacher et al., 1988</xref>), and <italic>f<sub>u, brain</sub></italic> is the unbound fraction of brain. The published <italic>in vivo</italic> brain permeability values were unified to observed <italic>PS</italic> (<italic>PS<sub>Obs</sub></italic>) by multiplying by <italic>VSA</italic> equal to 150 cm<sup>2</sup>/g. If <italic>PS<sub>Pre</sub></italic> values were within 0.5- to 2.0-folds of observations, the prediction was considered successful.</p></sec><sec id="s4-17"><title>Statistical analyses</title><p>All results are presented as mean ± SEM. The average of technical replicates generated a single independent value that contributes to the <italic>n</italic> value used for comparative statistical analysis. The data were assessed for Gaussian distributions using Shapiro–Wilk test. Brown–Forsythe test was employed to evaluate the homogeneity of variance between groups. For comparisons between two groups, statistical significance was determined by unpaired two-tailed <italic>t</italic>-test. The acquired data with significant variation were tested using unpaired <italic>t</italic>-test with Welch’s correction, and non-Gaussian distributed data were tested using Mann–Whitney test. For multiple group comparisons, one-way ANOVA followed by Fisher’s LSD test was used to determine statistical significance. The acquired data with significant variation were tested using Welch’s ANOVA test, and non-Gaussian distributed data were tested using Kruskal–Wallis test. p &lt; 0.05 was considered statistically significant. The simple linear regression analysis was used to examine the presence of a linear relationship between two variables. Data were analyzed using GraphPad Prism software version 8.0.2 (GraphPad Software, La Jolla, CA, USA).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>Software, Visualization</p></fn><fn fn-type="con" id="con4"><p>Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Data curation</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Funding acquisition</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Resources, Supervision, Funding acquisition, Project administration</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health). The protocol was approved by the Animal Ethics Committee of China Pharmaceutical University (Approval Number: 202307003). All surgery was performed under isoflurane anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-96161-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data are available in the manuscript and supporting files; source data files have been provided for Figures 1–6 and Table 1. Source data 1 and Source data 2 files of Figures 1–6 contain original files of western blots. Source data 3 files of Figures 1–6 and Table 1—source data 1 contain the numerical data used to generate the figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors would like to give special thanks to the support of the China Pharmaceutical University Pharmaceutical Animal Laboratory Center.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Blood–brain barrier structure and function and the challenges for CNS drug delivery</article-title><source>Journal of Inherited Metabolic Disease</source><volume>36</volume><fpage>437</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1007/s10545-013-9608-0</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvanitis</surname><given-names>CD</given-names></name><name><surname>Ferraro</surname><given-names>GB</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The blood–brain barrier and blood–tumour barrier in brain tumours and metastases</article-title><source>Nature Reviews Cancer</source><volume>20</volume><fpage>26</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0205-x</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asada</surname><given-names>S</given-names></name><name><surname>Daitoku</surname><given-names>H</given-names></name><name><surname>Matsuzaki</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Sudo</surname><given-names>T</given-names></name><name><surname>Mukai</surname><given-names>H</given-names></name><name><surname>Iwashita</surname><given-names>S</given-names></name><name><surname>Kako</surname><given-names>K</given-names></name><name><surname>Kishi</surname><given-names>T</given-names></name><name><surname>Kasuya</surname><given-names>Y</given-names></name><name><surname>Fukamizu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1</article-title><source>Cellular Signalling</source><volume>19</volume><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2006.08.015</pub-id><pub-id pub-id-type="pmid">17113751</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avdeef</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A new in situ brain perfusion flow correction method for lipophilic drugs based on the pH-dependent Crone-Renkin equation</article-title><source>Pharmaceutical Research</source><volume>28</volume><fpage>517</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1007/s11095-010-0298-0</pub-id><pub-id pub-id-type="pmid">21042838</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery</article-title><source>Nature Reviews Drug Discovery</source><volume>15</volume><fpage>275</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1038/nrd.2015.21</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barberio</surname><given-names>C</given-names></name><name><surname>Withers</surname><given-names>A</given-names></name><name><surname>Mishra</surname><given-names>Y</given-names></name><name><surname>Couraud</surname><given-names>P-O</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Weksler</surname><given-names>B</given-names></name><name><surname>Owens</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A human-derived neurovascular unit <italic>in vitro</italic> model to study the effects of cellular cross-talk and soluble factors on barrier integrity</article-title><source>Frontiers in Cellular Neuroscience</source><volume>16</volume><elocation-id>1065193</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2022.1065193</pub-id><pub-id pub-id-type="pmid">36545654</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beard</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>Hoettels</surname><given-names>BA</given-names></name><name><surname>Meegan</surname><given-names>JE</given-names></name><name><surname>Wertz</surname><given-names>TS</given-names></name><name><surname>Cha</surname><given-names>BJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Oxford</surname><given-names>JT</given-names></name><name><surname>Wu</surname><given-names>MH</given-names></name><name><surname>Yuan</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>AKT2 maintains brain endothelial claudin-5 expression and selective activation of IR/AKT2/FOXO1-signaling reverses barrier dysfunction</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>40</volume><fpage>374</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1177/0271678X18817512</pub-id><pub-id pub-id-type="pmid">30574832</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhallamudi</surname><given-names>S</given-names></name><name><surname>Roos</surname><given-names>BB</given-names></name><name><surname>Teske</surname><given-names>JJ</given-names></name><name><surname>Wicher</surname><given-names>SA</given-names></name><name><surname>McConico</surname><given-names>A</given-names></name><name><surname>M Pabelick</surname><given-names>C</given-names></name><name><surname>Sathish</surname><given-names>V</given-names></name><name><surname>Prakash</surname><given-names>YS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Glial-derived neurotrophic factor in human airway smooth muscle</article-title><source>Journal of Cellular Physiology</source><volume>236</volume><fpage>8184</fpage><lpage>8196</lpage><pub-id pub-id-type="doi">10.1002/jcp.30489</pub-id><pub-id pub-id-type="pmid">34170009</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>C</given-names></name><name><surname>Masters</surname><given-names>AR</given-names></name><name><surname>Bach</surname><given-names>C</given-names></name><name><surname>Stratford</surname><given-names>RE</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2021">2021</year><article-title>Population model analysis of chiral inversion and degradation of bupropion enantiomers, and application to enantiomer specific fraction unbound determination in rat plasma and brain</article-title><source>Journal of Pharmaceutical and Biomedical Analysis</source><volume>195</volume><elocation-id>113872</elocation-id><pub-id pub-id-type="doi">10.1016/j.jpba.2020.113872</pub-id><pub-id pub-id-type="pmid">33388643</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhyrapuneni</surname><given-names>G</given-names></name><name><surname>Thentu</surname><given-names>JB</given-names></name><name><surname>Palacharla</surname><given-names>VRC</given-names></name><name><surname>Muddana</surname><given-names>N</given-names></name><name><surname>Aleti</surname><given-names>RR</given-names></name><name><surname>Ajjala</surname><given-names>DR</given-names></name><name><surname>Nirogi</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A definite measure of occupancy exposures, seeking with non-radiolabeled in vivo 5-HT2A receptor occupancy and in vitro free fractions</article-title><source>Journal of Receptor and Signal Transduction Research</source><volume>38</volume><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1080/10799893.2018.1531888</pub-id><pub-id pub-id-type="pmid">30481094</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>S</given-names></name><name><surname>Cottarelli</surname><given-names>A</given-names></name><name><surname>Agalliu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neuronal and glial regulation of CNS angiogenesis and barriergenesis</article-title><source>Development</source><volume>147</volume><elocation-id>dev182279</elocation-id><pub-id pub-id-type="doi">10.1242/dev.182279</pub-id><pub-id pub-id-type="pmid">32358096</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowman</surname><given-names>CM</given-names></name><name><surname>Benet</surname><given-names>LZ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation</article-title><source>European Journal of Pharmaceutical Sciences</source><volume>123</volume><fpage>502</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2018.08.008</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulldan</surname><given-names>A</given-names></name><name><surname>Dietze</surname><given-names>R</given-names></name><name><surname>Shihan</surname><given-names>M</given-names></name><name><surname>Scheiner-Bobis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Non-classical testosterone signaling mediated through ZIP9 stimulates claudin expression and tight junction formation in Sertoli cells</article-title><source>Cellular Signalling</source><volume>28</volume><fpage>1075</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2016.04.015</pub-id><pub-id pub-id-type="pmid">27164415</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clasadonte</surname><given-names>J</given-names></name><name><surname>Prevot</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The special relationship: glia-neuron interactions in the neuroendocrine hypothalamus</article-title><source>Nature Reviews. Endocrinology</source><volume>14</volume><fpage>25</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2017.124</pub-id><pub-id pub-id-type="pmid">29076504</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colás-Algora</surname><given-names>N</given-names></name><name><surname>García-Weber</surname><given-names>D</given-names></name><name><surname>Cacho-Navas</surname><given-names>C</given-names></name><name><surname>Barroso</surname><given-names>S</given-names></name><name><surname>Caballero</surname><given-names>A</given-names></name><name><surname>Ribas</surname><given-names>C</given-names></name><name><surname>Correas</surname><given-names>I</given-names></name><name><surname>Millán</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Compensatory increase of VE-cadherin expression through ETS1 regulates endothelial barrier function in response to TNFα</article-title><source>Cellular and Molecular Life Sciences</source><volume>77</volume><fpage>2125</fpage><lpage>2140</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03260-9</pub-id><pub-id pub-id-type="pmid">31396656</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremers</surname><given-names>TIFH</given-names></name><name><surname>Flik</surname><given-names>G</given-names></name><name><surname>Hofland</surname><given-names>C</given-names></name><name><surname>Stratford</surname><given-names>RE</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2012">2012</year><article-title>Microdialysis evaluation of clozapine and N-desmethylclozapine pharmacokinetics in rat brain</article-title><source>Drug Metabolism and Disposition</source><volume>40</volume><fpage>1909</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1124/dmd.112.045682</pub-id><pub-id pub-id-type="pmid">22736307</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejana</surname><given-names>E</given-names></name><name><surname>Orsenigo</surname><given-names>F</given-names></name><name><surname>Lampugnani</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The role of adherens junctions and VE-cadherin in the control of vascular permeability</article-title><source>Journal of Cell Science</source><volume>121</volume><fpage>2115</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.1242/jcs.017897</pub-id><pub-id pub-id-type="pmid">18565824</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di</surname><given-names>L</given-names></name><name><surname>Umland</surname><given-names>JP</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Scott</surname><given-names>DO</given-names></name><name><surname>Troutman</surname><given-names>MD</given-names></name><name><surname>Liston</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Species independence in brain tissue binding using brain homogenates</article-title><source>Drug Metabolism and Disposition</source><volume>39</volume><fpage>1270</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1124/dmd.111.038778</pub-id><pub-id pub-id-type="pmid">21474681</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di</surname><given-names>L</given-names></name><name><surname>Breen</surname><given-names>C</given-names></name><name><surname>Chambers</surname><given-names>R</given-names></name><name><surname>Eckley</surname><given-names>ST</given-names></name><name><surname>Fricke</surname><given-names>R</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Harradine</surname><given-names>P</given-names></name><name><surname>Kalvass</surname><given-names>JC</given-names></name><name><surname>Ho</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>CA</given-names></name><name><surname>Marathe</surname><given-names>P</given-names></name><name><surname>Perkins</surname><given-names>EJ</given-names></name><name><surname>Qian</surname><given-names>M</given-names></name><name><surname>Tse</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Zamek-Gliszczynski</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug-drug interaction and related guidelines on highly bound drugs</article-title><source>Journal of Pharmaceutical Sciences</source><volume>106</volume><fpage>3442</fpage><lpage>3452</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.09.005</pub-id><pub-id pub-id-type="pmid">28927987</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marco</surname><given-names>A</given-names></name><name><surname>Gonzalez Paz</surname><given-names>O</given-names></name><name><surname>Fini</surname><given-names>I</given-names></name><name><surname>Vignone</surname><given-names>D</given-names></name><name><surname>Cellucci</surname><given-names>A</given-names></name><name><surname>Battista</surname><given-names>MR</given-names></name><name><surname>Auciello</surname><given-names>G</given-names></name><name><surname>Orsatti</surname><given-names>L</given-names></name><name><surname>Zini</surname><given-names>M</given-names></name><name><surname>Monteagudo</surname><given-names>E</given-names></name><name><surname>Khetarpal</surname><given-names>V</given-names></name><name><surname>Rose</surname><given-names>M</given-names></name><name><surname>Dominguez</surname><given-names>C</given-names></name><name><surname>Herbst</surname><given-names>T</given-names></name><name><surname>Toledo-Sherman</surname><given-names>L</given-names></name><name><surname>Summa</surname><given-names>V</given-names></name><name><surname>Muñoz-Sanjuán</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Application of an in vitro blood-brain barrier model in the selection of experimental drug candidates for the treatment of huntington’s disease</article-title><source>Molecular Pharmaceutics</source><volume>16</volume><fpage>2069</fpage><lpage>2082</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00042</pub-id><pub-id pub-id-type="pmid">30916978</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Ubogu</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GDNF enhances human blood-nerve barrier function in vitro via MAPK signaling pathways</article-title><source>Tissue Barriers</source><volume>6</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1080/21688370.2018.1546537</pub-id><pub-id pub-id-type="pmid">30523753</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eigenmann</surname><given-names>DE</given-names></name><name><surname>Xue</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Moses</surname><given-names>AV</given-names></name><name><surname>Hamburger</surname><given-names>M</given-names></name><name><surname>Oufir</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies</article-title><source>Fluids and Barriers of the CNS</source><volume>10</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1186/2045-8118-10-33</pub-id><pub-id pub-id-type="pmid">24262108</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esaki</surname><given-names>T</given-names></name><name><surname>Ohashi</surname><given-names>R</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><name><surname>Natsume-Kitatani</surname><given-names>Y</given-names></name><name><surname>Kawashima</surname><given-names>H</given-names></name><name><surname>Nagao</surname><given-names>C</given-names></name><name><surname>Mizuguchi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Computational model to predict the fraction of unbound drug in the brain</article-title><source>Journal of Chemical Information and Modeling</source><volume>59</volume><fpage>3251</fpage><lpage>3261</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.9b00180</pub-id><pub-id pub-id-type="pmid">31260629</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenstermacher</surname><given-names>J</given-names></name><name><surname>Gross</surname><given-names>P</given-names></name><name><surname>Sposito</surname><given-names>N</given-names></name><name><surname>Acuff</surname><given-names>V</given-names></name><name><surname>Pettersen</surname><given-names>S</given-names></name><name><surname>Gruber</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Structural and functional variations in capillary systems within the brain</article-title><source>Annals of the New York Academy of Sciences</source><volume>529</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1988.tb51416.x</pub-id><pub-id pub-id-type="pmid">3395069</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fielder</surname><given-names>GC</given-names></name><name><surname>Yang</surname><given-names>TW-S</given-names></name><name><surname>Razdan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Perry</surname><given-names>JK</given-names></name><name><surname>Lobie</surname><given-names>PE</given-names></name><name><surname>Liu</surname><given-names>D-X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The gdnf family: a role in cancer?</article-title><source>Neoplasia</source><volume>20</volume><fpage>99</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2017.10.010</pub-id><pub-id pub-id-type="pmid">29245123</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridén</surname><given-names>M</given-names></name><name><surname>Bergström</surname><given-names>F</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Rehngren</surname><given-names>M</given-names></name><name><surname>Ahlin</surname><given-names>G</given-names></name><name><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><name><surname>Bredberg</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods</article-title><source>Drug Metabolism and Disposition</source><volume>39</volume><fpage>353</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1124/dmd.110.035998</pub-id><pub-id pub-id-type="pmid">21149540</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Huo</surname><given-names>D</given-names></name><name><surname>Zhi</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Astrocyte-derived TGFβ1 facilitates blood-brain barrier function via non-canonical hedgehog signaling in brain microvascular endothelial cells</article-title><source>Brain Sciences</source><volume>11</volume><elocation-id>77</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci11010077</pub-id><pub-id pub-id-type="pmid">33430164</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanafy</surname><given-names>AS</given-names></name><name><surname>Dietrich</surname><given-names>D</given-names></name><name><surname>Fricker</surname><given-names>G</given-names></name><name><surname>Lamprecht</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Blood-brain barrier models: Rationale for selection</article-title><source>Advanced Drug Delivery Reviews</source><volume>176</volume><elocation-id>113859</elocation-id><pub-id pub-id-type="doi">10.1016/j.addr.2021.113859</pub-id><pub-id pub-id-type="pmid">34246710</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Greene</surname><given-names>C</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The CLDN5 gene at the blood-brain barrier in health and disease</article-title><source>Fluids and Barriers of the CNS</source><volume>20</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1186/s12987-023-00424-5</pub-id><pub-id pub-id-type="pmid">36978081</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatherell</surname><given-names>K</given-names></name><name><surname>Couraud</surname><given-names>P-O</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Weksler</surname><given-names>B</given-names></name><name><surname>Pilkington</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models</article-title><source>Journal of Neuroscience Methods</source><volume>199</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2011.05.012</pub-id><pub-id pub-id-type="pmid">21609734</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Q-F</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>C-Z</given-names></name><name><surname>Wei</surname><given-names>W-C</given-names></name><name><surname>Chen</surname><given-names>L-P</given-names></name><name><surname>Li</surname><given-names>H-Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Melatonin protects against hyperoxia-induced apoptosis in alveolar epithelial type ii cells by activating the mt2/pi3k/akt/ets1 signaling pathway</article-title><source>Lung</source><volume>201</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/s00408-023-00610-0</pub-id><pub-id pub-id-type="pmid">36928143</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo-Figueroa</surname><given-names>M</given-names></name><name><surname>Bonilla</surname><given-names>S</given-names></name><name><surname>Gutiérrez</surname><given-names>F</given-names></name><name><surname>Pascual</surname><given-names>A</given-names></name><name><surname>López-Barneo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>GDNF is predominantly expressed in the PV+ neostriatal interneuronal ensemble in normal mouse and after injury of the nigrostriatal pathway</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>864</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2693-11.2012</pub-id><pub-id pub-id-type="pmid">22262884</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hsieh</surname><given-names>J-T</given-names></name><name><surname>Chang</surname><given-names>LS</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer</article-title><source>Cellular Signalling</source><volume>48</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2018.04.006</pub-id><pub-id pub-id-type="pmid">29702203</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>Y</given-names></name><name><surname>Utsumi</surname><given-names>H</given-names></name><name><surname>Chiba</surname><given-names>H</given-names></name><name><surname>Yamada-Sasamori</surname><given-names>Y</given-names></name><name><surname>Tobioka</surname><given-names>H</given-names></name><name><surname>Kamimura</surname><given-names>Y</given-names></name><name><surname>Furuuchi</surname><given-names>K</given-names></name><name><surname>Kokai</surname><given-names>Y</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Sawada</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier</article-title><source>Biochemical and Biophysical Research Communications</source><volume>261</volume><fpage>108</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1999.0992</pub-id><pub-id pub-id-type="pmid">10405331</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>R</given-names></name><name><surname>Umehara</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Kitamura</surname><given-names>K</given-names></name><name><surname>Nunoya</surname><given-names>K-I</given-names></name><name><surname>Yamaura</surname><given-names>Y</given-names></name><name><surname>Imawaka</surname><given-names>H</given-names></name><name><surname>Izumi</surname><given-names>S</given-names></name><name><surname>Wakayama</surname><given-names>N</given-names></name><name><surname>Komori</surname><given-names>T</given-names></name><name><surname>Anzai</surname><given-names>N</given-names></name><name><surname>Akita</surname><given-names>H</given-names></name><name><surname>Furihata</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A human immortalized cell-based blood-brain barrier triculture model: development and characterization as a promising tool for drug-brain permeability studies</article-title><source>Molecular Pharmaceutics</source><volume>16</volume><fpage>4461</fpage><lpage>4471</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00519</pub-id><pub-id pub-id-type="pmid">31573814</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>B-S</given-names></name><name><surname>Cen</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y-Q</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Modulation of P-glycoprotein in rat brain microvessel endothelial cells under oxygen glucose deprivation</article-title><source>The Journal of Pharmacy and Pharmacology</source><volume>65</volume><fpage>1508</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1111/jphp.12122</pub-id><pub-id pub-id-type="pmid">24028618</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J-A</given-names></name><name><surname>Yanai</surname><given-names>R</given-names></name><name><surname>Nishida</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>IGF-1 released by corneal epithelial cells induces up-regulation of N-cadherin in corneal fibroblasts</article-title><source>Journal of Cellular Physiology</source><volume>221</volume><fpage>254</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1002/jcp.21850</pub-id><pub-id pub-id-type="pmid">19530221</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodaira</surname><given-names>H</given-names></name><name><surname>Kusuhara</surname><given-names>H</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Ushiki</surname><given-names>J</given-names></name><name><surname>Fuse</surname><given-names>E</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>339</volume><fpage>935</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1124/jpet.111.180398</pub-id><pub-id pub-id-type="pmid">21934030</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelièvre</surname><given-names>E</given-names></name><name><surname>Mattot</surname><given-names>V</given-names></name><name><surname>Huber</surname><given-names>P</given-names></name><name><surname>Vandenbunder</surname><given-names>B</given-names></name><name><surname>Soncin</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin</article-title><source>Oncogene</source><volume>19</volume><fpage>2438</fpage><lpage>2446</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203563</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelièvre</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The Ets family contains transcriptional activators and repressors involved in angiogenesis</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>33</volume><fpage>391</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(01)00025-5</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MS</given-names></name><name><surname>Cen</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CJY, an isoflavone, interacts with ATPase of P-glycoprotein in the rat brain microvessel endothelial cells (RBMECs)</article-title><source>Journal of Chemotherapy</source><volume>25</volume><fpage>347</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1179/1973947813Y.0000000094</pub-id><pub-id pub-id-type="pmid">24090809</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chin</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The role of ve-cadherin in blood-brain barrier integrity under central nervous system pathological conditions</article-title><source>Current Neuropharmacology</source><volume>16</volume><fpage>1375</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.2174/1570159X16666180222164809</pub-id><pub-id pub-id-type="pmid">29473514</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y-C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y-N</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>P-L</given-names></name><name><surname>Sun</surname><given-names>M-R</given-names></name><name><surname>Liu</surname><given-names>B-L</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Muscone and (+)-borneol cooperatively strengthen creb induction of claudin 5 in IL-1β-Induced endothelium injury</article-title><source>Antioxidants</source><volume>11</volume><elocation-id>1455</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11081455</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Bile duct ligation impairs function and expression of mrp1 at rat blood–retinal barrier via bilirubin-induced p38 mapk pathway activations</article-title><source>International Journal of Molecular Sciences</source><volume>23</volume><elocation-id>7666</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23147666</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C-H</given-names></name><name><surname>Wang</surname><given-names>C-H</given-names></name><name><surname>Hsu</surname><given-names>S-L</given-names></name><name><surname>Liao</surname><given-names>L-Y</given-names></name><name><surname>Lin</surname><given-names>T-A</given-names></name><name><surname>Hsueh</surname><given-names>C-M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular mechanisms responsible for neuron-derived conditioned medium (ncm)-mediated protection of ischemic brain</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0146692</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0146692</pub-id><pub-id pub-id-type="pmid">26745377</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>BJ</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Callegari</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cianfrogna</surname><given-names>J</given-names></name><name><surname>Doran</surname><given-names>AC</given-names></name><name><surname>Doran</surname><given-names>SD</given-names></name><name><surname>Gibbs</surname><given-names>JP</given-names></name><name><surname>Hosea</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>FR</given-names></name><name><surname>Szewc</surname><given-names>MA</given-names></name><name><surname>Van Deusen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>313</volume><fpage>1254</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.079319</pub-id><pub-id pub-id-type="pmid">15743928</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Mu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions</article-title><source>The Journal of Surgical Research</source><volume>238</volume><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2019.01.020</pub-id><pub-id pub-id-type="pmid">30771687</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chi</surname><given-names>T</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sigma-1 receptor activation alleviates blood-brain barrier disruption post cerebral ischemia stroke by stimulating the GDNF-GFRα1-RET pathway</article-title><source>Experimental Neurology</source><volume>347</volume><elocation-id>113867</elocation-id><pub-id pub-id-type="doi">10.1016/j.expneurol.2021.113867</pub-id><pub-id pub-id-type="pmid">34582837</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonka-Nevalaita</surname><given-names>L</given-names></name><name><surname>Lume</surname><given-names>M</given-names></name><name><surname>Leppänen</surname><given-names>S</given-names></name><name><surname>Jokitalo</surname><given-names>E</given-names></name><name><surname>Peränen</surname><given-names>J</given-names></name><name><surname>Saarma</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Characterization of the intracellular localization, processing, and secretion of two glial cell line-derived neurotrophic factor splice isoforms</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>11403</fpage><lpage>11413</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5888-09.2010</pub-id><pub-id pub-id-type="pmid">20739562</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>D-Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Endothelial ETS1 inhibition exacerbate blood–brain barrier dysfunction in multiple sclerosis through inducing endothelial-to-mesenchymal transition</article-title><source>Cell Death &amp; Disease</source><volume>13</volume><elocation-id>462</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-022-04888-5</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathiisen</surname><given-names>TM</given-names></name><name><surname>Lehre</surname><given-names>KP</given-names></name><name><surname>Danbolt</surname><given-names>NC</given-names></name><name><surname>Ottersen</surname><given-names>OP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction</article-title><source>Glia</source><volume>58</volume><fpage>1094</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1002/glia.20990</pub-id><pub-id pub-id-type="pmid">20468051</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>TS</given-names></name><name><surname>DeBartolo</surname><given-names>DB</given-names></name><name><surname>Tess</surname><given-names>DA</given-names></name><name><surname>Scott</surname><given-names>DO</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice</article-title><source>Drug Metabolism and Disposition</source><volume>33</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.001222</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>A</given-names></name><name><surname>Yamashita</surname><given-names>N</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>O</given-names></name><name><surname>Nakamura</surname><given-names>F</given-names></name><name><surname>Yagi</surname><given-names>T</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><name><surname>Usui</surname><given-names>H</given-names></name><name><surname>Katoh-Semba</surname><given-names>R</given-names></name><name><surname>Takei</surname><given-names>K</given-names></name><name><surname>Goshima</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regulation of dendritic branching and spine maturation by semaphorin3A-Fyn signaling</article-title><source>The Journal of Neuroscience</source><volume>26</volume><fpage>2971</fpage><lpage>2980</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5453-05.2006</pub-id><pub-id pub-id-type="pmid">16540575</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muoio</surname><given-names>V</given-names></name><name><surname>Persson</surname><given-names>PB</given-names></name><name><surname>Sendeski</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The neurovascular unit - concept review</article-title><source>Acta Physiologica</source><volume>210</volume><fpage>790</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1111/apha.12250</pub-id><pub-id pub-id-type="pmid">24629161</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Deli</surname><given-names>MA</given-names></name><name><surname>Kawaguchi</surname><given-names>H</given-names></name><name><surname>Shimizudani</surname><given-names>T</given-names></name><name><surname>Shimono</surname><given-names>T</given-names></name><name><surname>Kittel</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Niwa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes</article-title><source>Neurochemistry International</source><volume>54</volume><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2008.12.002</pub-id><pub-id pub-id-type="pmid">19111869</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitta</surname><given-names>T</given-names></name><name><surname>Hata</surname><given-names>M</given-names></name><name><surname>Gotoh</surname><given-names>S</given-names></name><name><surname>Seo</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>N</given-names></name><name><surname>Furuse</surname><given-names>M</given-names></name><name><surname>Tsukita</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice</article-title><source>The Journal of Cell Biology</source><volume>161</volume><fpage>653</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1083/jcb.200302070</pub-id><pub-id pub-id-type="pmid">12743111</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowrangi</surname><given-names>DS</given-names></name><name><surname>McBride</surname><given-names>D</given-names></name><name><surname>Manaenko</surname><given-names>A</given-names></name><name><surname>Dixon</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>rhIGF-1 reduces the permeability of the blood-brain barrier following intracerebral hemorrhage in mice</article-title><source>Experimental Neurology</source><volume>312</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2018.11.009</pub-id><pub-id pub-id-type="pmid">30503192</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsuki</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Kamoi</surname><given-names>M</given-names></name><name><surname>Asashima</surname><given-names>T</given-names></name><name><surname>Terasaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells</article-title><source>Journal of Cellular Physiology</source><volume>210</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/jcp.20823</pub-id><pub-id pub-id-type="pmid">16998798</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsuki</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>C</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Sakamoto</surname><given-names>Y</given-names></name><name><surname>Miller</surname><given-names>F</given-names></name><name><surname>Glacial</surname><given-names>F</given-names></name><name><surname>Decleves</surname><given-names>X</given-names></name><name><surname>Scherrmann</surname><given-names>J-M</given-names></name><name><surname>Couraud</surname><given-names>P-O</given-names></name><name><surname>Kubo</surname><given-names>Y</given-names></name><name><surname>Tachikawa</surname><given-names>M</given-names></name><name><surname>Terasaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model</article-title><source>Molecular Pharmaceutics</source><volume>10</volume><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1021/mp3004308</pub-id><pub-id pub-id-type="pmid">23137377</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmiotti</surname><given-names>CA</given-names></name><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Naik</surname><given-names>P</given-names></name><name><surname>Abul</surname><given-names>KMD</given-names></name><name><surname>Sajja</surname><given-names>RK</given-names></name><name><surname>Achyuta</surname><given-names>AH</given-names></name><name><surname>Cucullo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>In vitro cerebrovascular modeling in the 21st century: current and prospective technologies</article-title><source>Pharmaceutical Research</source><volume>31</volume><fpage>3229</fpage><lpage>3250</lpage><pub-id pub-id-type="doi">10.1007/s11095-014-1464-6</pub-id><pub-id pub-id-type="pmid">25098812</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pochon</surname><given-names>NA</given-names></name><name><surname>Menoud</surname><given-names>A</given-names></name><name><surname>Tseng</surname><given-names>JL</given-names></name><name><surname>Zurn</surname><given-names>AD</given-names></name><name><surname>Aebischer</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization</article-title><source>The European Journal of Neuroscience</source><volume>9</volume><fpage>463</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.1997.tb01623.x</pub-id><pub-id pub-id-type="pmid">9104588</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potjewyd</surname><given-names>G</given-names></name><name><surname>Moxon</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Domingos</surname><given-names>M</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tissue engineering 3d neurovascular units: a biomaterials and bioprinting perspective</article-title><source>Trends in Biotechnology</source><volume>36</volume><fpage>457</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2018.01.003</pub-id><pub-id pub-id-type="pmid">29422410</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A review on in vitro model of the blood-brain barrier (BBB) based on hCMEC/D3 cells</article-title><source>Journal of Controlled Release</source><volume>358</volume><fpage>78</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.04.020</pub-id><pub-id pub-id-type="pmid">37076016</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sajja</surname><given-names>RK</given-names></name><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Cucullo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Impact of altered glycaemia on blood-brain barrier endothelium: an in vitro study using the hCMEC/D3 cell line</article-title><source>Fluids and Barriers of the CNS</source><volume>11</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1186/2045-8118-11-8</pub-id><pub-id pub-id-type="pmid">24708805</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saker</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>EA</given-names></name><name><surname>Browning</surname><given-names>AC</given-names></name><name><surname>Allen</surname><given-names>CL</given-names></name><name><surname>Amoaku</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The effect of hyperglycaemia on permeability and the expression of junctional complex molecules in human retinal and choroidal endothelial cells</article-title><source>Experimental Eye Research</source><volume>121</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2014.02.016</pub-id><pub-id pub-id-type="pmid">24594192</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sánchez-Dengra</surname><given-names>B</given-names></name><name><surname>González-Álvarez</surname><given-names>I</given-names></name><name><surname>Sousa</surname><given-names>F</given-names></name><name><surname>Bermejo</surname><given-names>M</given-names></name><name><surname>González-Álvarez</surname><given-names>M</given-names></name><name><surname>Sarmento</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>In vitro model for predicting the access and distribution of drugs in the brain using hCMEC/D3 cells</article-title><source>European Journal of Pharmaceutics and Biopharmaceutics</source><volume>163</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2021.04.002</pub-id><pub-id pub-id-type="pmid">33838261</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauteur</surname><given-names>L</given-names></name><name><surname>Affolter</surname><given-names>M</given-names></name><name><surname>Belting</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Distinct and redundant functions of Esama and VE-cadherin during vascular morphogenesis</article-title><source>Development</source><volume>144</volume><fpage>1554</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1242/dev.140038</pub-id><pub-id pub-id-type="pmid">28264837</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savettieri</surname><given-names>G</given-names></name><name><surname>Di Liegro</surname><given-names>I</given-names></name><name><surname>Catania</surname><given-names>C</given-names></name><name><surname>Licata</surname><given-names>L</given-names></name><name><surname>Pitarresi</surname><given-names>GL</given-names></name><name><surname>D’Agostino</surname><given-names>S</given-names></name><name><surname>Schiera</surname><given-names>G</given-names></name><name><surname>De Caro</surname><given-names>V</given-names></name><name><surname>Giandalia</surname><given-names>G</given-names></name><name><surname>Giannola</surname><given-names>LI</given-names></name><name><surname>Cestelli</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Neurons and ECM regulate occludin localization in brain endothelial cells</article-title><source>Neuroreport</source><volume>11</volume><fpage>1081</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1097/00001756-200004070-00035</pub-id><pub-id pub-id-type="pmid">10790886</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiera</surname><given-names>G</given-names></name><name><surname>Bono</surname><given-names>E</given-names></name><name><surname>Raffa</surname><given-names>MP</given-names></name><name><surname>Gallo</surname><given-names>A</given-names></name><name><surname>Pitarresi</surname><given-names>GL</given-names></name><name><surname>Di Liegro</surname><given-names>I</given-names></name><name><surname>Savettieri</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Synergistic effects of neurons and astrocytes on the differentiation of brain capillary endothelial cells in culture</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>7</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2003.tb00215.x</pub-id><pub-id pub-id-type="pmid">12927055</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiera</surname><given-names>G</given-names></name><name><surname>Sala</surname><given-names>S</given-names></name><name><surname>Gallo</surname><given-names>A</given-names></name><name><surname>Raffa</surname><given-names>MP</given-names></name><name><surname>Pitarresi</surname><given-names>GL</given-names></name><name><surname>Savettieri</surname><given-names>G</given-names></name><name><surname>Di Liegro</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Permeability properties of a three-cell type in vitro model of blood-brain barrier</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>9</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2005.tb00362.x</pub-id><pub-id pub-id-type="pmid">15963256</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>F</given-names></name><name><surname>Sano</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>M-A</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Ohtsuki</surname><given-names>S</given-names></name><name><surname>Terasaki</surname><given-names>T</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors</article-title><source>Journal of Cellular Physiology</source><volume>226</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1002/jcp.22337</pub-id><pub-id pub-id-type="pmid">20665675</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>F</given-names></name><name><surname>Sano</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Haruki</surname><given-names>H</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier</article-title><source>Neurochemical Research</source><volume>37</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1007/s11064-011-0626-8</pub-id><pub-id pub-id-type="pmid">22002662</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Summerfield</surname><given-names>SG</given-names></name><name><surname>Read</surname><given-names>K</given-names></name><name><surname>Begley</surname><given-names>DJ</given-names></name><name><surname>Obradovic</surname><given-names>T</given-names></name><name><surname>Hidalgo</surname><given-names>IJ</given-names></name><name><surname>Coggon</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>AV</given-names></name><name><surname>Porter</surname><given-names>RA</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>322</volume><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1124/jpet.107.121525</pub-id><pub-id pub-id-type="pmid">17405866</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>MD</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Montagne</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>AR</given-names></name><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Blood-brain barrier: from physiology to disease and back</article-title><source>Physiological Reviews</source><volume>99</volume><fpage>21</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1152/physrev.00050.2017</pub-id><pub-id pub-id-type="pmid">30280653</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taddei</surname><given-names>A</given-names></name><name><surname>Giampietro</surname><given-names>C</given-names></name><name><surname>Conti</surname><given-names>A</given-names></name><name><surname>Orsenigo</surname><given-names>F</given-names></name><name><surname>Breviario</surname><given-names>F</given-names></name><name><surname>Pirazzoli</surname><given-names>V</given-names></name><name><surname>Potente</surname><given-names>M</given-names></name><name><surname>Daly</surname><given-names>C</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Dejana</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5</article-title><source>Nature Cell Biology</source><volume>10</volume><fpage>923</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1038/ncb1752</pub-id><pub-id pub-id-type="pmid">18604199</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>ED</given-names></name><name><surname>Nuñez</surname><given-names>G</given-names></name><name><surname>Barr</surname><given-names>FG</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Negative regulation of the forkhead transcription factor fkhr by akt</article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>16741</fpage><lpage>16746</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.24.16741</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tavelin</surname><given-names>S</given-names></name><name><surname>Gråsjö</surname><given-names>J</given-names></name><name><surname>Taipalensuu</surname><given-names>J</given-names></name><name><surname>Ocklind</surname><given-names>G</given-names></name><name><surname>Artursson</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><chapter-title>Applications of epithelial cell culture in studies of drug transport</chapter-title><person-group person-group-type="editor"><name><surname>Wise</surname><given-names>C</given-names></name></person-group><source>Epithelial Cell Culture Protocols</source><publisher-loc>Totowa, NJ</publisher-loc><publisher-name>Humana Press</publisher-name><fpage>233</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1385/1-59259-185-x:233</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunggal</surname><given-names>JA</given-names></name><name><surname>Helfrich</surname><given-names>I</given-names></name><name><surname>Schmitz</surname><given-names>A</given-names></name><name><surname>Schwarz</surname><given-names>H</given-names></name><name><surname>Günzel</surname><given-names>D</given-names></name><name><surname>Fromm</surname><given-names>M</given-names></name><name><surname>Kemler</surname><given-names>R</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name><name><surname>Niessen</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>1146</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600605</pub-id><pub-id pub-id-type="pmid">15775979</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z-G</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>X-C</given-names></name><name><surname>Ye</surname><given-names>L-B</given-names></name><name><surname>Xia</surname><given-names>Q-H</given-names></name><name><surname>Johnson</surname><given-names>NR</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D-Q</given-names></name><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Fu</surname><given-names>X-B</given-names></name><name><surname>Li</surname><given-names>X-K</given-names></name><name><surname>Zhang</surname><given-names>H-Y</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>bFGF protects against blood-brain barrier damage through junction protein regulation via pi3k-akt-rac1 pathway following traumatic brain injury</article-title><source>Molecular Neurobiology</source><volume>53</volume><fpage>7298</fpage><lpage>7311</lpage><pub-id pub-id-type="doi">10.1007/s12035-015-9583-6</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>D</given-names></name><name><surname>Takagi</surname><given-names>H</given-names></name><name><surname>Suzuma</surname><given-names>K</given-names></name><name><surname>Suzuma</surname><given-names>I</given-names></name><name><surname>Oh</surname><given-names>H</given-names></name><name><surname>Ohashi</surname><given-names>H</given-names></name><name><surname>Kemmochi</surname><given-names>S</given-names></name><name><surname>Uemura</surname><given-names>A</given-names></name><name><surname>Ojima</surname><given-names>T</given-names></name><name><surname>Suganami</surname><given-names>E</given-names></name><name><surname>Miyamoto</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Transcription factor ets-1 mediates ischemia- and vascular endothelial growth factor-dependent retinal neovascularization</article-title><source>The American Journal of Pathology</source><volume>164</volume><fpage>1827</fpage><lpage>1835</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63741-8</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>D</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Morofuji</surname><given-names>Y</given-names></name><name><surname>Tóth</surname><given-names>AE</given-names></name><name><surname>Vastag</surname><given-names>M</given-names></name><name><surname>Aruga</surname><given-names>J</given-names></name><name><surname>Niwa</surname><given-names>M</given-names></name><name><surname>Deli</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characterization of a primate blood-brain barrier co-culture model prepared from primary brain endothelial cells, pericytes and astrocytes</article-title><source>Pharmaceutics</source><volume>13</volume><elocation-id>1484</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13091484</pub-id><pub-id pub-id-type="pmid">34575559</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>ML</given-names></name><name><surname>Hofland</surname><given-names>CM</given-names></name><name><surname>Shaffer</surname><given-names>CL</given-names></name><name><surname>Flik</surname><given-names>G</given-names></name><name><surname>Cremers</surname><given-names>T</given-names></name><name><surname>Hurst</surname><given-names>RS</given-names></name><name><surname>Rollema</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Therapeutic doses of antidepressants are projected not to inhibit human α4β2 nicotinic acetylcholine receptors</article-title><source>Neuropharmacology</source><volume>72</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.04.027</pub-id><pub-id pub-id-type="pmid">23639435</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weksler</surname><given-names>B</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Couraud</surname><given-names>P-O</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The hCMEC/D3 cell line as a model of the human blood brain barrier</article-title><source>Fluids and Barriers of the CNS</source><volume>10</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/2045-8118-10-16</pub-id><pub-id pub-id-type="pmid">23531482</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>Y-Y</given-names></name><name><surname>Kong</surname><given-names>W-M</given-names></name><name><surname>Jin</surname><given-names>M-M</given-names></name><name><surname>Yang</surname><given-names>H-Y</given-names></name><name><surname>Zheng</surname><given-names>X-K</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X-D</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Bile duct ligation causes opposite impacts on the expression and function of BCRP and P-gp in rat brain partly via affecting membrane expression of ezrin/radixin/moesin proteins</article-title><source>Acta Pharmacologica Sinica</source><volume>42</volume><fpage>1942</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-00602-3</pub-id><pub-id pub-id-type="pmid">33558655</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A novel brain neurovascular unit model with neurons</article-title><source>Astrocytes and Microvascular Endothelial Cells of Rat. International Journal of Biological Sciences</source><volume>9</volume><fpage>174</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.7150/ijbs.5115</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Mu</surname><given-names>R</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Hepatic retinaldehyde deficiency is involved in diabetes deterioration by enhancing PCK1- and G6PC-mediated gluconeogenesis</article-title><source>Acta Pharmaceutica Sinica. B</source><volume>13</volume><fpage>3728</fpage><lpage>3743</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.06.014</pub-id><pub-id pub-id-type="pmid">37719384</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Hadden</surname><given-names>TJ</given-names></name><name><surname>Rishi</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Akt, FoxO and regulation of apoptosis</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1813</volume><fpage>1978</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.03.010</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Nelson</surname><given-names>FR</given-names></name><name><surname>Zelesky</surname><given-names>V</given-names></name><name><surname>Troutman</surname><given-names>MD</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice</article-title><source>Drug Metabolism and Disposition</source><volume>37</volume><fpage>946</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.024489</pub-id><pub-id pub-id-type="pmid">19225039</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Increase in P-glycoprotein levels in the blood-brain barrier of partial portal vein ligation /chronic hyperammonemia rats is medicated by ammonia/reactive oxygen species/ERK1/2 activation: In vitro and in vivo studies</article-title><source>European Journal of Pharmacology</source><volume>846</volume><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2019.01.005</pub-id><pub-id pub-id-type="pmid">30639310</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96161.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Velasco</surname><given-names>Ivan</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Universidad Nacional Autónoma de México</institution><country>Mexico</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This revised study presents <bold>valuable</bold> evidence that a combination of endothelial cells, astrocytes, and neuroblastoma cells of human origin can integrate to form an <italic>in vitro</italic> brain blood barrier, that recapitulates key aspects of its natural counterpart, especially at short times. <bold>Convincingly</bold>, the mechanism by which neuroblastoma-secreted GDNF increases Claudin-5 and VE-cadherin is described. To substantiate the role of GDNF in vivo, authors demonstrated that knock-down of this neurotrophic factor, increased the permeability of the brain blood barrier in mice. This <italic>in vitro</italic> system can be used to study the permeability of the human brain blood barrier to different drugs.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96161.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This paper by Yang et al. established an <italic>in vitro</italic> triple co-culture BBB model and demonstrated its advantages compared with the mono or double co-culture BBB model. Further, the authors used their established <italic>in vitro</italic> BBB model and combined it with other methodologies to investigate the specific signaling mechanisms that co-culture with astrocytes but also neurons enhancing the integrity of endothelial cells.</p><p>Strengths:</p><p>The results persuasively demonstrated that the established triple co-culture BBB model well mimicked several important characteristics of BBB compared with the mono-culture BBB model, including better barrier function and <italic>in vivo</italic>/<italic>in vitro</italic> correlation. The use of human-derived immortalized cells made the model construction process faster and more efficient and had a better <italic>in vivo</italic> correlation without the complications of species differences. This model is expected to be a useful high-throughput evaluation tool for CNS drug development.</p><p>Moreover, the authors used a variety of experiments to prove that the triple co-culture model also reflected the interactions between NVU cells, including promoting endothelial cell proliferation and the formation of intercellular junctions. Interestingly, the authors found that neurons also released GDNF to promote barrier properties of brain endothelial cells, as most current research has focused on the promoting effect of astrocytes-derived GDNF on BBB. Meanwhile, the author also validated the functions of GDNF for BBB integrity <italic>in vivo</italic> by silencing GDNF in mouse brains. Overall, the experiments and data presented support the claim that neurons, alongside astrocytes, contribute to the promoting effects of the barrier function of endothelial cells through GDNF secretion.</p><p>Weaknesses:</p><p>While the authors explained that the use of human-derived immortalized cells has been justified as more reproducible and efficient in constructing the model, the TEER value of the triple co-culture model remains lower than that of the physiological statement. Future research may need to explore additional methods to further enhance the barrier function of the model.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96161.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Yang and colleagues developed a new <italic>in vitro</italic> blood-brain barrier model that is relatively simple yet outperforms previous models. By incorporating a neuroblastoma cell line, they demonstrated increased electrical resistance and decreased permeability to small molecules</p><p>Strengths:</p><p>The authors initially elucidated the soluble mediator responsible for enhancing endothelial functionality, namely GDNF. Subsequently, they elucidated the mechanisms by which GDNF upregulates the expression of VE-cadherin and Claudin-5. They further validated these findings <italic>in vivo</italic>, and demonstrated predictive value for molecular permeability as well. The study is meticulously conducted and easily comprehensible. The conclusions are firmly supported by the data, and the objectives are successfully achieved. This research is poised to advance future investigations in BBB permeability, leakage, dysfunction, disease modeling, and drug delivery, particularly in high-throughput experiments. I anticipate an enthusiastic reception from the community interested in this area. While other studies have produced similar results with tri-cultures (PMID: 25630899), this study notably enhances electrical resistance compared to previous attempts.</p><p>Weaknesses:</p><p>The power of this system lies in its simplicity, which is enough to study BBB permeability. However, it also lacks some other important cell-cell interactions such as those involving pericytes. Nonetheless, this is still a valuable tool for high throughput screening.</p><p>As with many other similar systems, it has lower TEER values compared to the <italic>in vivo</italic> counterpart, this is an issue that researchers in the field will have to address in future studies</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96161.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Lu</given-names></name><role specific-use="author">Author</role><aff><institution>China Pharmaceutical University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Zijin</given-names></name><role specific-use="author">Author</role><aff><institution>China Pharmaceutical University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Mu</surname><given-names>Ruijing</given-names></name><role specific-use="author">Author</role><aff><institution>China Pharmaceutical University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Wenhan</given-names></name><role specific-use="author">Author</role><aff><institution>China Pharmaceutical University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhi</surname><given-names>Hao</given-names></name><role specific-use="author">Author</role><aff><institution>China Pharmaceutical University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaodong</given-names></name><role specific-use="author">Author</role><aff><institution>China Pharmaceutical University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Hanyu</given-names></name><role specific-use="author">Author</role><aff><institution>China Pharmaceutical University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Li</given-names></name><role specific-use="author">Author</role><aff><institution>China Pharmaceutical University</institution><addr-line><named-content content-type="city">Nanjing</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>In this manuscript, the authors established an <italic>in vitro</italic> triple co-culture BBB model and demonstrated its advantages compared with the mono or double co-culture BBB model. Further, the authors used their established <italic>in vitro</italic> BBB model and combined it with other methodologies to investigate the specific mechanism that co-culture with astrocytes but also neurons enhanced the integrity of endothelial cells.</p><p>Strengths:</p><p>The results persuasively showed the established triple co-culture BBB model well mimicked several important characteristics of BBB compared with the mono-culture BBB model, including better barrier function and <italic>in vivo</italic>/<italic>in vitro</italic> correlation. The human-derived immortalized cells used made the model construction process faster and more efficient, and have a better <italic>in vivo</italic> correlation without species differences. This model is expected to be a useful high-throughput evaluation tool in the development of CNS drugs.</p><p>Based on the previous experimental results, detailed studies investigated how co-culture with neurons and astrocytes promoted claudin-5 and VE-cadherin in endothelial cells, and the specific signaling mechanisms were also studied. Interestingly, the authors found that neurons also released GDNF to promote barrier properties of brain endothelial cells, as most current research has focused on the promoting effect of astrocytes-derived GDNF on BBB. Meanwhile, the author also validated the functions of GDNF for BBB integrity <italic>in vivo</italic> by silencing GDNF in mouse brains. Overall, the experiments and data presented support their claim that, in addition to astrocytes, neurons also have a promoting effect on the barrier function of endothelial cells through GDNF secretion.</p><p>Weaknesses:</p><p>Although the authors demonstrated a highly usable for predicting the BBB permeability, recorded TEER measurements are still far from the human BBB <italic>in vivo</italic> reported measurements of TEER, and expression of transporters was not promoted by co-culture, which may lead to the model being unsuitable for studying drug transport mediated by transporters on BBB.</p></disp-quote><p>Thank the reviewer very much for the opportunity to improve our manuscript. The immortalized human cell lines, hCMEC/D3 cell, have poor barrier properties and differences in the expression of some transporters and metabolic enzymes as well as TEER compared to human physiological BBB. However, the use of human primary BMECs may be restricted by the acquisition of materials and ethical approval. Isolation and purification of human primary BMECs are time-consuming and laborious. Moreover, culture conditions can alter transcriptional activity (<italic>PMID</italic>: 37076016). All limit the establishment of BBB models based on primary human BMECs for high-throughput screening. Thus, hCMEC/D3 is still widely used to study characteristics of drug transport across BBB and the effects of certain diseases on BBB (<italic>PMID</italic>: 37076016; 38711118; 31163193) as it is easy to culture and can express a large number of transporters and metabolic enzymes in its physiological state. Therefore, hCMEC/D3 cells were selected to develop our <italic>in vitro</italic> BBB model.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Point 1: The authors claim that GDNF is mainly released by human neuroblastoma SH-SY5Y cells in the <italic>in vitro</italic> BBB model, but there are still some differences between the characteristics of cell lines and neurons. The authors should discuss or provide evidence about the distribution and source of GDNF in the brain to support this conclusion.</p></disp-quote><p>We greatly appreciate your helpful suggestions. According to your advice, we have revised the “Discussion” in the revised manuscript as follows:</p><p>In “Discussion”:</p><p>“GDNF is mainly expressed in astrocytes and neurons (Lonka-Nevalaita et al., 2010; Pochon et al., 1997). In adult animals, GDNF is mainly secreted by striatal neurons rather than astrocytes and microglial cells (Hidalgo-Figueroa et al., 2012). The present study also shows that GDNF mRNA levels in SH-SY5Y cells were significantly higher than that in U251 cells. GDNF was also detected in conditioned medium from SH-SY5Y cells. All these results demonstrate that neurons may secrete GDNF”.</p><disp-quote content-type="editor-comment"><p>Point 2: The authors found that co-culture induced the proliferation of endothelial cells (Figure 1H). I suggest the authors discuss whether the proliferation of endothelial cells would affect their permeability.</p></disp-quote><p>Thanks for your suggestion. According to your advice, we have investigated the effect of cell proliferation on the leakage of the cell layer and included the results in Figure 1—figure supplement 1. The present study showed that basic fibroblast growth factor (bFGF) increased cell proliferation of hCMEC/D3 cells but little affected the expression of both claudin-5 and VE-cadherin (in Figure 2F). The hCMEC/D3 cells were incubated with different doses of bFGF and permeabilities of fluorescein (NaF) and FITC-Dextran 3–5 kDa across hCMEC/D3 cell monolayer were measured. The results showed that incubation with bFGF increased cell proliferation and reduced permeabilities of fluorescein and FITC-Dextran across hCMEC/D3 cell monolayer. However, the permeability reduction was less than that by double co-culture with U251 cells or triple co-culture. These results inferred that contribution of cell proliferation to the barrier function of hCMEC/D3 cells was minor. We have made the modifications in “Results” of our manuscript as follows:</p><p>In “Result”:</p><p>“Furthermore, hCMEC/D3 cells were incubated with basic fibroblast growth factor (bFGF), which promotes cell proliferation without affecting both claudin-5 and VE-cadherin expression (Figure 2F). The results showed that incubation with bFGF increased cell proliferation and reduced permeabilities of fluorescein and FITC-Dex across hCMEC/D3 cell monolayer. However, the permeability reduction was less than that by double co-culture with U251 cells or triple co-culture. These results inferred that contribution of cell proliferation to the barrier function of hCMEC/D3 was minor (Figure 1—figure supplement 1)”.</p><disp-quote content-type="editor-comment"><p>Point 3: The authors claimed that GDNF induced the expression of claudin-5 and VE-cadherin separately. However, Andrea Taddei et al. reported that VE-cadherin itself also regulates claudin-5 through the inhibitory activity of FoxO1 (Andrea Taddei et al., 2008). The authors did not consider whether the upregulation of claudin-5 is associated with the increase of VE-cadherin.</p></disp-quote><p>Thank you for your suggestion. We also investigated whether VE-cadherin affected claudin-5 expression in hCMEC/D3 cells transfected with VE-cadherin siRNA. It was not consistent with the report by Taddei et al. that silencing VE-cadherin only slightly decreased the mRNA level of claudin-5 without significant difference. Furthermore, basal and GDNF-induced claudin-5 protein levels were unaltered by silencing VE-cadherin. The discrepancies may come from characteristics of the tested cells. Endothelial cells derived from murine embryonic stem cells with homozygous null mutation were used in Taddei’s study, while we transfected immortalized brain microvascular endothelial cells with siRNA. Several reports have demonstrated different mechanisms regulating expression of claudin-5 and VE-cadherin. In retinal endothelial cells, hyperglycemia remarkably reduced claudin-5 expression (but not VE-cadherin) (<italic>PMID</italic>: 24594192). However, in hCMEC/D3 cells, hypoglycemia significantly decreased claudin-5 (not VE-cadherin) expression but hyperglycemia increased VE-cadherin expression (not claudin 5) (<italic>PMID</italic>: 24708805). Therefore, the roles of VE-cadherin in regulation of claudin-5 in BBB should be further investigated.</p><p>Following your valuable suggestion, we have modified the “Results”, “Discussion” and “Figure 4—figure supplement 1” in the revised manuscript as follows:</p><p>In “Result”:</p><p>“It was reported that VE-cadherin also upregulates claudin-5 via inhibiting FOXO1 activities (Taddei et al, 2008). Effect of VE-cadherin on claudin-5 was studied in hCMEC/D3 cells silencing VE-cadherin. It was not consistent with the report by Taddei et al. that silencing VE-cadherin only slightly decreased the mRNA level of claudin-5 without significant difference. Furthermore, basal and GDNF-induced claudin-5 protein levels were unaltered by silencing VE-cadherin (Figure 4—figure supplement 1). Thus, the roles of VE-cadherin in regulation of claudin-5 in BBB should be further investigated.”</p><p>In “Discussion”:</p><p>“Claudin-5 expression is also regulated by VE-cadherin (Taddei et al., 2008). Differing from the previous reports, silencing VE-cadherin with siRNA only slightly affected basal and GDNF-induced claudin-5 expression. The discrepancies may come from different characteristics of the tested cells. Several reports have supported the above deduction. In retinal endothelial cells, hyperglycemia remarkably reduced claudin-5 expression (but not VE-cadherin) (Saker et al., 2014). However, in hCMEC/D3 cells, hypoglycemia significantly decreased claudin-5 expression but hyperglycemia increased VE-cadherin expression (Sajja et al., 2014)”.</p><p>“Figure 4—figure supplement 1: The contribution of VE-Cadherin on the GDNF-induced claudin-5 expression. Effects of the VE-Cadherin siRNA (siVE-Cad) on mRNA expression of VE-cadherin (A) and claudin-5 (B). Effects of siVE-Cad and GDNF on claudin-5 and VE-cadherin protein expression (C). NC: negative control plasmids. The above data are shown as the mean ± SEM. Four biological replicates per group. Two technical replicates for A and B, and one technical replicate for C. Statistical significance was determined using unpaired Student’s t-test or one-way ANOVA test followed by Fisher’s LSD test.”</p><disp-quote content-type="editor-comment"><p>Point 4: The annotation of significance with the p-values in the figures might not be visually concise and clear. It is recommended to provide the p-values in the legends or raw data.</p></disp-quote><p>Thank you for your valuable suggestion. We have revised our figures in our revised manuscript. The specific <italic>p</italic>-values and statistical methods were summarized in the source data files of each figure.</p><disp-quote content-type="editor-comment"><p>Point 5: The authors need to note the material of the Transwell membrane used to increase the reproducibility of experiments, because different materials may cause differences in permeability and TEER (DianeM. Wuest et al., 2013).</p></disp-quote><p>We greatly appreciate your valuable suggestions. According to your advice, we have provided the information on the material of the Transwell membrane in the “Materials and Methods” in the revised manuscript as follows:</p><p>In “Materials and Methods”:</p><p>“U251 cells were seeded at 2 × 10<sup>4</sup> cells/cm<sup>2</sup> on the bottom of Transwell inserts (PET, 0.4 µm pore size, SPL Life Sciences, Pocheon, Korea) coated with rat-tail collagen (Corning Inc, Corning, NY, USA)”.</p><disp-quote content-type="editor-comment"><p>Point 6: It is not necessary to abbreviate &quot;<italic>in vitro</italic>/<italic>in vivo</italic> correlation&quot; in the legend of Figure 7 as it was not mentioned again in the following text.</p></disp-quote><p>Thank you for your valuable suggestion. We have deleted the abbreviation of &quot;Figure 7&quot; of the revised manuscript.</p><p>In “Figure 7”</p><p>“Figure 7. <italic>In vitro</italic>/<italic>in vivo</italic> correlation assay of BBB permeability.&quot;</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>Yang and colleagues developed a new <italic>in vitro</italic> blood-brain barrier model that is relatively simple yet outperforms previous models. By incorporating a neuroblastoma cell line, they demonstrated increased electrical resistance and decreased permeability to small molecules.</p><p>Strengths:</p><p>The authors initially elucidated the soluble mediator responsible for enhancing endothelial functionality, namely GDNF. Subsequently, they elucidated the mechanisms by which GDNF upregulates the expression of VE-cadherin and Claudin-5. They further validated these findings <italic>in vivo</italic>, and demonstrated predictive value for molecular permeability as well. The study is meticulously conducted and easily comprehensible. The conclusions are firmly supported by the data, and the objectives are successfully achieved. This research is poised to advance future investigations in BBB permeability, leakage, dysfunction, disease modeling, and drug delivery, particularly in high-throughput experiments. I anticipate an enthusiastic reception from the community interested in this area. While other studies have produced similar results with tri-cultures (PMID: 25630899), this study notably enhances electrical resistance compared to previous attempts.</p><p>Weaknesses:</p><p>(A) Considerable effort has been directed towards developing <italic>in vitro</italic> models that more closely resemble their <italic>in vivo</italic> counterparts, utilizing stem cell-derived NVU cells. Although these examples are currently rudimentary, they offer better BBB mimicry than Yang's study.</p></disp-quote><p>Thank you very much for your valuable comments. Indeed, hCMEC/D3 cells, have poor barrier properties and low TEER compared to human physiological BBB. The human pluripotent stem cells BBB models (hPSC-BBB models) make it possible to provide a robust and scalable cell source for BBB modeling, although many challenges remain, particularly concerning reproducibility and recreation of multifaceted phenotypes <italic>in vitro</italic> with increasing complexity. Moreover, the hPSC-derived BBB models are highly dependent upon the heterogeneous incorporation of hPSC-derived BMEC origins, cells derived from different protocols are not well validated and standardized in the BBB models. Thus, the hPSC-BBB models are still being developed and their clinic applications are still at an early stage (<italic>PMID</italic>: 34815809; 35755780). The hCMEC/D3 cell line is still widely used to study characteristics of drug transport across BBB and the effects of certain diseases on BBB (<italic>PMID</italic>: 37076016; 38711118; 31163193) as it is easy to culture and can express a large number of transporters and metabolic enzymes in its physiological state. Therefore, hCMEC/D3 cells were selected to develop our <italic>in vitro</italic> BBB model.</p><disp-quote content-type="editor-comment"><p>(B) Additionally, some instances might benefit from more robust statistical tests; nonetheless, I do not think this would significantly alter the experimental conclusions.</p></disp-quote><p>Thank you for your valuable suggestions on the statistical methods used in our study, which made us realize our lack of rigor in selecting statistical methods. We have made modifications to statistical methods, and all statistical results showed the manuscript have been updated accordingly.</p><disp-quote content-type="editor-comment"><p>(C) Similar experiments with tri-cultures yielding analogous results have been reported by other authors (PMID: 25630899). TEER values are a bit higher than the aforementioned experiments; however, this study has values at least one order of magnitude lower than physiological levels.</p></disp-quote><p>Thank your advice. We also noticed that TEER values in the present study were different from previous reports, which may come from types of BEMCs, astrocytes, and neurons.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Point 1: If you've already decided to enhance the model by incorporating additional cell types, why not include pericytes as well? As mentioned in the public review, other studies have explored tri-culture models; adding pericytes or other cell types could provide valuable insights.</p></disp-quote><p>We greatly appreciate your helpful suggestions. As you mentioned, the barrier function of our model still needs further improvement, which is also a limitation of our current model. In our future research, we will aim to optimize our model by incorporating other NVU cells. Beyond drug screening, we also hope that our <italic>in vitro</italic> BBB model can serve as a versatile tool to investigate underlying factors associated with neuropathological disorders. According to your advice, we have modified “Discussion” in the revised manuscript as follows:</p><p>In “Discussion”:</p><p>“However, the study also has some limitations. In addition to neurons and astrocytes, other cells such as microglia, pericytes, and vascular smooth muscle cells, especially pericytes, may also affect BBB function. How pericytes affect BBB function and interaction among neurons, astrocytes, and pericytes needs further investigation.”</p><disp-quote content-type="editor-comment"><p>Point 2: The decline in TEER after 6 days is concerning. Have you extended your experiments beyond day 7? If so, what were the outcomes? Did the system degrade, leading to decreased resistance, or did cell death occur?</p></disp-quote><p>We greatly appreciate your helpful recommendation. We also observed that the TEER of our culture system began to decline on day 7. To ensure the reliability of our experiments, our experiments were conducted on day 6 of co-cultivation and did not extend beyond day 7. We speculate that the reason for the decrease in TEER values may be due to excessive cell contact, which could inhibit cell proliferation and long-term cultivation may lead to cell aging. Similar results showing a decrease in TEER of <italic>in vitro</italic> BBB models after prolonged culture have been reported in other studies (<italic>PMID</italic>: 31079318; 8470770). To eliminate misunderstandings, we have made the following modifications to our manuscript:</p><p>In “Result”:</p><p>“TEER values were measured during the co-culture (Figure 1B)<italic>.</italic> TEER values of the four <italic>in vitro</italic> BBB models gradually increased until day 6. On day 7, the TEER values showed a decreasing trend. Thus, six-day co-culture period was used for subsequent experiments”.</p><p>In “<italic>In vitro</italic> BBB permeability study” of “Materials and Methods”:</p><p>“On day 7, the TEER values of BBB models showed a decreasing trend. Therefore, the subsequent experiments were all completed on day 6”.</p><disp-quote content-type="editor-comment"><p>Point 3: It is standard practice for figures to be referenced in the order they appear in the manuscript. However, Figures 1A and 1B are not mentioned until the end of the methods section. Adding a brief sentence at the beginning of the main body referencing these figures would improve the clarity of the experimental approach.</p></disp-quote><p>Thank you for your valuable suggestion. We had made modifications to Figure 1, and the details of the cell model establishment process had been included in Figure 9 which is mentioned in the “Materials and Methods” section.</p><disp-quote content-type="editor-comment"><p>Point 4: To strengthen the evidence supporting the proliferative effect of GDNF, consider incorporating additional measures beyond cell count alone. While an increase in cell count could be attributed to reduced cell death (given GDNF's pro-survival properties), proliferation effects have also been shown (PMID: 28878618). I suggest demonstrating proliferation with markers or cell cycle analysis would provide more robust evidence.</p></disp-quote><p>Thank you for your helpful suggestion. We used EdU incorporation and CCK-8 assays to further detect the proliferation of hCMEC/D3 cells, and corresponding results were added in the revised Figure 1H and Figure 1I. The description of results is shown as follows:</p><p>In “Results”:</p><p>“Co-culture with SH-SY5Y, U251, and U251 + SH-SY5Y cells also enhanced the proliferation of hCMEC/D3 cells. Moreover, the promoting effect of SH-SY5Y cells was stronger than that of U251 cells (Figure 1G-I).”</p><disp-quote content-type="editor-comment"><p>Point 5: Could you specify the use of technical replicates in your experiments? How many?</p></disp-quote><p>Thank you for your helpful suggestion, and we apologize for the issue you pointed out. We have now specified the technical replicates of experiments in the legends of the revised manuscript. In general, the technical replicate number of ELISA and qPCR is two, and that of the rest experiments is one. And we have also made the following modifications to our manuscript:</p><p>In “Statistical analyses” of “Materials and Methods”:</p><p>“All results are presented as mean ± SEM. The average of technical replicates generated a single independent value that contributes to the n value used for comparative statistical analysis”.</p><disp-quote content-type="editor-comment"><p>Point 6: Given the sample size of 4 in most experiments, it may be insufficient for passing a normality test. Therefore, it's advisable to employ non-parametric tests such as the Kruskal-Wallis test, followed by appropriate post-hoc tests.</p></disp-quote><p>Thank you for your valuable and useful suggestion. We apologize for our initial oversight regarding statistics. Based on your suggestion, we have thoroughly reviewed and revised the statistical methods and statistical results in the manuscript. Referring to the ‘Statistics Guide’ of GraphPad (H. J. Motulsky, &quot;The power of nonparametric tests&quot;, GraphPad Statistics Guide. Accessed 20 June 2024. <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/guides/prism/latest/statistics/stat_the_power_of_nonparametric_tes.htm">https://www.graphpad.com/guides/prism/latest/statistics/stat_the_power_of_nonparametric_tes.htm</ext-link>), the Kruskal-Wallis test is more robust when the data does not follow a normal distribution or homogeneity of variance. However, due to its reliance on ranks, it may have lower sensitivity in detecting small differences. If the total sample size is tiny, the Kruskal-Wallis test will always give a P value greater than 0.05 no matter how much the groups differ. To address this, we first used the Shapiro-Wilk test to assume whether the samples come from Gaussian distributions. For samples meeting this criterion, parametric tests were employed. For samples that do not follow the Gaussian distribution, as per your advice, we utilized the non-parametric tests. We have modified the “Statistical analyses” in the revised manuscript as follows:</p><p>In “Statistical analyses” of “Materials and Methods”:</p><p>“The data were assessed for Gaussian distributions using Shapiro-Wilk test. Brown-Forsythe test was employed to evaluate the homogeneity of variance between groups. For comparisons between two groups, statistical significance was determined by unpaired 2-tailed t-test. The acquired data with significant variation were tested using unpaired t-test with Welch's correction, and non-Gaussian distributed data were tested using Mann-Whitney test. For multiple group comparisons, one-way ANOVA followed by Fisher’s LSD test was used to determine statistical significance. The acquired data with significant variation were tested using Welch's ANOVA test, and non-Gaussian distributed data were tested using Kruskal-Wallis test. p &lt; 0.05 was considered statistically significant. The simple linear regression analysis was used to examine the presence of a linear relationship between two variables. Data were analyzed using GraphPad Prism software version 8.0.2 (GraphPad Software, La Jolla, CA, USA)”.</p></body></sub-article></article>